<!DOCTYPE html><html lang="en" class="bg-surface-base antialiased"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1, interactive-widget=resizes-content"/><link rel="stylesheet" href="/_next/static/css/62c4caba71dfda84.css" nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/eb3d87f98fe1565f.css" nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/1b5e561215938d4d.css" nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/0227d069a630d414.css" nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/f87fff2ab93d05a7.css" nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy" data-precedence="next"/><link rel="preload" as="script" fetchPriority="low" nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy" href="/_next/static/chunks/webpack-e121ed42680f327e.js"/><script src="/_next/static/chunks/78a669d9-e7993486b22c4915.js" async="" nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy"></script><script src="/_next/static/chunks/40c4a5a7-abdabb07419d1cfc.js" async="" nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy"></script><script src="/_next/static/chunks/2230-f7c87dc9fa57c408.js" async="" nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy"></script><script src="/_next/static/chunks/main-app-536d4b8fca62396a.js" async="" nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy"></script><script src="/_next/static/chunks/63f0ec43-8ee6a76d70472249.js" async="" nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy"></script><script src="/_next/static/chunks/7670-7326298c9856172b.js" async="" nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy"></script><script src="/_next/static/chunks/282-691fffb366e24ca5.js" async="" nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy"></script><script src="/_next/static/chunks/7515-336759ef5dad2b52.js" async="" nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy"></script><script src="/_next/static/chunks/927-34e2a6da3e15e26b.js" async="" nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy"></script><script src="/_next/static/chunks/5855-243eeca8f0e4cabd.js" async="" nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy"></script><script src="/_next/static/chunks/4393-1c8dff25ec904469.js" async="" nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy"></script><script src="/_next/static/chunks/2225-454cf9f44775e7ce.js" async="" nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy"></script><script src="/_next/static/chunks/7618-43536a8fb0dd3bfe.js" async="" nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js" async="" nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy"></script><script src="/_next/static/chunks/7720-3a1e7e411adba2d3.js" async="" nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy"></script><script src="/_next/static/chunks/7086-1f1c4891d766e04f.js" async="" nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js" async="" nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy"></script><script src="/_next/static/chunks/app/global-error-4d07d20223cd4b4c.js" async="" nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy"></script><script src="/_next/static/chunks/8208b75a-a48e5a4507a0de91.js" async="" nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy"></script><script src="/_next/static/chunks/5497-ab85ef3ea59dd353.js" async="" nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy"></script><script src="/_next/static/chunks/6281-c6e84786dade3614.js" async="" nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy"></script><script src="/_next/static/chunks/2660-d983a7f287e89f18.js" async="" nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy"></script><script src="/_next/static/chunks/5002-9735c25beda556ba.js" async="" nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy"></script><script src="/_next/static/chunks/3655-6717081f7512305a.js" async="" nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy"></script><script src="/_next/static/chunks/8945-e4e3cf487f5e27c7.js" async="" nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy"></script><script src="/_next/static/chunks/9214-a10614844a67ba31.js" async="" nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy"></script><script src="/_next/static/chunks/4789-2080f6497f78b5b6.js" async="" nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy"></script><script src="/_next/static/chunks/app/layout-226f2bd71acf9f9e.js" async="" nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy"></script><script src="/_next/static/chunks/24cf1b50-159cca90b09285e0.js" async="" nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy"></script><script src="/_next/static/chunks/9ffa21ba-c069766d809bd4c7.js" async="" nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy"></script><script src="/_next/static/chunks/600-9a9fcafaaa6c1c4c.js" async="" nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy"></script><script src="/_next/static/chunks/5448-2a3cfd853d899c9a.js" async="" nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy"></script><script src="/_next/static/chunks/8-8ca70ca619d8e099.js" async="" nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js" async="" nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy"></script><script src="/_next/static/chunks/app/error-4a29e9399afba038.js" async="" nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy"></script><script src="/_next/static/chunks/app/not-found-dd95690acf732f18.js" async="" nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy"></script><meta name="next-size-adjust" content=""/><title>Grokipedia</title><meta name="description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><link rel="icon" type="image/x-icon" href="/favicon.ico" sizes="48x48"/><link rel="icon" href="/images/icon-dark.png" media="(prefers-color-scheme: light)" type="image/png"/><link rel="icon" href="/images/icon-light.png" media="(prefers-color-scheme: dark)" type="image/png"/><link rel="apple-touch-icon" href="/icon-192x192.png"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><meta property="og:title" content="Grokipedia"/><meta property="og:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta property="og:url" content="https://grokipedia.com"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en_US"/><meta property="og:type" content="website"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Grokipedia"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Grokipedia"/><meta name="twitter:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><title>Apalutamide</title><meta name="description" content="Apalutamide , sold under the brand name Erleada among others, is a nonsteroidal antiandrogen (NSAA) medication used for the treatment of prostate cancer, including non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC).[2][8][9][8] It is an androgen receptor inhibitor.[2] It is taken by mouth.[2][10] Side effects of apalutamide when added to castration include fatigue, nausea, abdominal pain, diarrhea, high blood pressure, rash,..."/><meta name="author" content="system"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="keywords" content="Erleada, ARN-509"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><link rel="canonical" href="https://grokipedia.com/page/Apalutamide"/><meta property="og:title" content="Apalutamide"/><meta property="og:description" content="Apalutamide , sold under the brand name Erleada among others, is a nonsteroidal antiandrogen (NSAA) medication used for the treatment of prostate cancer, including non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC).[2][8][9][8] It is an androgen receptor inhibitor.[2] It is taken by mouth.[2][10] Side effects of apalutamide when added to castration include fatigue, nausea, abdominal pain, diarrhea, high blood pressure, rash,..."/><meta property="og:url" content="https://grokipedia.com/page/Apalutamide"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Apalutamide"/><meta property="og:type" content="article"/><meta property="article:modified_time" content="1970-01-21T09:19:13.636Z"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Apalutamide"/><meta name="twitter:description" content="Apalutamide , sold under the brand name Erleada among others, is a nonsteroidal antiandrogen (NSAA) medication used for the treatment of prostate cancer, including non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC).[2][8][9][8] It is an androgen receptor inhibitor.[2] It is taken by mouth.[2][10] Side effects of apalutamide when added to castration include fatigue, nausea, abdominal pain, diarrhea, high blood pressure, rash,..."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><link rel="icon" href="/favicon.ico" type="image/x-icon" sizes="16x16"/><meta name="sentry-trace" content="428ec8f3a49272c08666b2c046f9fec8-f930d8a14d81e33d-1"/><meta name="baggage" content="sentry-environment=production,sentry-public_key=5f2258f71198ee26a355127af230c3a6,sentry-trace_id=428ec8f3a49272c08666b2c046f9fec8,sentry-org_id=4508179396558848,sentry-transaction=GET%20%2Fpage%2F%5Bslug%5D,sentry-sampled=true,sentry-sample_rand=0.9862987086548725,sentry-sample_rate=1"/><script src="/_next/static/chunks/polyfills-42372ed130431b0a.js" noModule="" nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy"></script></head><body class="flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b"><div hidden=""><!--$--><!--/$--></div><script nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy">((a,b,c,d,e,f,g,h)=>{let i=document.documentElement,j=["light","dark"];function k(b){var c;(Array.isArray(a)?a:[a]).forEach(a=>{let c="class"===a,d=c&&f?e.map(a=>f[a]||a):e;c?(i.classList.remove(...d),i.classList.add(f&&f[b]?f[b]:b)):i.setAttribute(a,b)}),c=b,h&&j.includes(c)&&(i.style.colorScheme=c)}if(d)k(d);else try{let a=localStorage.getItem(b)||c,d=g&&"system"===a?window.matchMedia("(prefers-color-scheme: dark)").matches?"dark":"light":a;k(d)}catch(a){}})("class","theme","dark",null,["light","dark"],null,true,true)</script><header class="h-16 bg-surface-base fixed top-0 z-50 w-full"><div class="hidden h-full grid-cols-[1fr_3fr_1fr] items-center gap-4 !py-0 md:grid max-w-full py-6 px-4 w-full mx-auto"><div class="-ml-2 justify-self-start"><a class="cursor-pointer" href="/"><svg width="200" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="mx-auto flex w-full"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full px-3 shadow-none sm:w-80 focus-visible:z-1 mx-auto h-full w-full rounded-full bg-surface-l1" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>âŒ˜</span><span class="text-xs">K</span></div></span></div></button></div><div class="flex items-center gap-2 justify-self-end"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0" type="button" id="radix-_R_7apfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button></div></div><div class="flex h-full items-center md:hidden justify-between max-w-full py-6 px-4 w-full mx-auto pt-8"><div class="flex items-center"><div class="-ml-2"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button" aria-label="Toggle table of contents"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-list h-6 w-6"><path d="M3 12h.01"></path><path d="M3 18h.01"></path><path d="M3 6h.01"></path><path d="M8 12h13"></path><path d="M8 18h13"></path><path d="M8 6h13"></path></svg></button></div><a class="cursor-pointer" href="/"><svg width="160" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="flex items-center gap-1"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0 [&amp;_svg]:!w-5" type="button" id="radix-_R_aipfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-search h-5 w-5"><circle cx="11" cy="11" r="8"></circle><path d="m21 21-4.3-4.3"></path></svg></button></div></div></header><div class="bg-surface-base fixed right-0 top-16 z-50 h-[calc(100vh-4rem)] w-full transform border-l transition-transform duration-300 ease-in-out sm:w-1/2 md:hidden translate-x-full"><div class="flex flex-col gap-4 p-4"><div class="flex flex-row gap-2"><button class="focus-visible:ring-ring inline-flex items-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full shadow-none sm:w-80 h-10 w-full justify-start rounded-full bg-surface-l1 px-4" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>âŒ˜</span><span class="text-xs">K</span></div></span></div></button></div></div></div><div><div class="min-[1350px]:grid min-[1350px]:grid-cols-[1fr_3fr_1fr]"><nav class="bg-surface-base hidden h-[calc(100vh-4rem)] overflow-y-auto px-6 pb-32 min-[1350px]:sticky min-[1350px]:top-16 min-[1350px]:block scrollbar-none [-ms-overflow-style:none] [scrollbar-width:none] [&amp;::-webkit-scrollbar]:hidden [overscroll-behavior:contain] pt-8"><ul class="space-y-2 text-sm"><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#apalutamide" class="transition-opacity hover:opacity-100 opacity-50">Apalutamide</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#clinical-data" class="transition-opacity hover:opacity-100 opacity-50">Clinical data</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#legal-status" class="transition-opacity hover:opacity-100 opacity-50">Legal status</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#pharmacokinetic-data" class="transition-opacity hover:opacity-100 opacity-50">Pharmacokinetic data</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#identifiers" class="transition-opacity hover:opacity-100 opacity-50">Identifiers</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#chemical-and-physical-data" class="transition-opacity hover:opacity-100 opacity-50">Chemical and physical data</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#medical-uses" class="transition-opacity hover:opacity-100 opacity-50">Medical uses</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#contraindications" class="transition-opacity hover:opacity-100 opacity-50">Contraindications</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#side-effects" class="transition-opacity hover:opacity-100 opacity-50">Side effects</a></li><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#overdose" class="transition-opacity hover:opacity-100 opacity-50">Overdose</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#interactions" class="transition-opacity hover:opacity-100 opacity-50">Interactions</a></li><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#pharmacology" class="transition-opacity hover:opacity-100 opacity-50">Pharmacology</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#pharmacodynamics" class="transition-opacity hover:opacity-100 opacity-50">Pharmacodynamics</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#antiandrogenic-activity" class="transition-opacity hover:opacity-100 opacity-50">Antiandrogenic activity</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#other-activities" class="transition-opacity hover:opacity-100 opacity-50">Other activities</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#pharmacokinetics" class="transition-opacity hover:opacity-100 opacity-50">Pharmacokinetics</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#chemistry" class="transition-opacity hover:opacity-100 opacity-50">Chemistry</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#history" class="transition-opacity hover:opacity-100 opacity-50">History</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#society-and-culture" class="transition-opacity hover:opacity-100 opacity-50">Society and culture</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#generic-names" class="transition-opacity hover:opacity-100 opacity-50">Generic names</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#brand-names" class="transition-opacity hover:opacity-100 opacity-50">Brand names</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#availability" class="transition-opacity hover:opacity-100 opacity-50">Availability</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#references" class="transition-opacity hover:opacity-100 opacity-50">References</a></li></ul></nav><div class="relative top-16 pb-32 pt-8 px-4 md:px-8"><div class="mx-auto max-w-[850px]"><button data-state="closed" type="button" class="flex items-center"><div class="text-fg-tertiary mb-2 flex cursor-help items-center gap-2 text-sm"><span class="inline-flex items-center justify-center p-0 m-0" data-namespace="@xai/icons" data-slot="icon" style="height:16px;width:16px"><svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 33 33" aria-hidden="true" class="" focusable="false" style="fill:currentColor;height:16px;width:16px"><path fill="currentColor" d="m13.237 21.04 11.082-8.19c.543-.4 1.32-.244 1.578.38 1.363 3.288.754 7.241-1.957 9.955-2.71 2.714-6.482 3.31-9.93 1.954l-3.765 1.745c5.401 3.697 11.96 2.782 16.059-1.324 3.251-3.255 4.258-7.692 3.317-11.693l.008.009c-1.365-5.878.336-8.227 3.82-13.031q.123-.17.247-.345l-4.585 4.59v-.014L13.234 21.044M10.95 23.031c-3.877-3.707-3.208-9.446.1-12.755 2.446-2.449 6.454-3.448 9.952-1.979L24.76 6.56c-.677-.49-1.545-1.017-2.54-1.387A12.465 12.465 0 0 0 8.675 7.901c-3.519 3.523-4.625 8.94-2.725 13.561 1.42 3.454-.907 5.898-3.251 8.364-.83.874-1.664 1.749-2.335 2.674l10.583-9.466"></path></svg></span><span>Fact-checked by Grok<!-- --> <!-- -->4 days ago</span></div></button><article class="text-[16px]"><h1 id="apalutamide" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Apalutamide<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<span class="mb-4 block break-words text-[1em] leading-7"><strong>Apalutamide</strong> , sold under the brand name <strong>Erleada</strong> among others, is a <span class="inline text-[1em] leading-7">nonsteroidal antiandrogen</span> (NSAA) medication used for the treatment of <span class="inline text-[1em] leading-7">prostate cancer</span>, including non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_bqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> It is an <span class="inline text-[1em] leading-7">androgen receptor</span> inhibitor.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> It is taken <span class="inline text-[1em] leading-7">by mouth</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_kqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_lqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Side effects</span> of apalutamide when added to castration include <span class="inline text-[1em] leading-7">fatigue</span>, <span class="inline text-[1em] leading-7">nausea</span>, <span class="inline text-[1em] leading-7">abdominal pain</span>, <span class="inline text-[1em] leading-7">diarrhea</span>, <span class="inline text-[1em] leading-7">high blood pressure</span>, <span class="inline text-[1em] leading-7">rash</span>, <span class="inline text-[1em] leading-7">falls</span>, <span class="inline text-[1em] leading-7">bone fractures</span>, and an <span class="inline text-[1em] leading-7">underactive thyroid</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_l1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_m1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_n1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_o1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_p1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup> Rarely, it can cause <span class="inline text-[1em] leading-7">seizures</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_t1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_u1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup> The medication has a high potential for <span class="inline text-[1em] leading-7">drug interactions</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_121abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_131abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup> Apalutamide is an <span class="inline text-[1em] leading-7">antiandrogen</span>, and acts as an <span class="inline text-[1em] leading-7">antagonist</span> of the <span class="inline text-[1em] leading-7">androgen receptor</span>, the <span class="inline text-[1em] leading-7">biological target</span> of <span class="inline text-[1em] leading-7">androgens</span> like <span class="inline text-[1em] leading-7">testosterone</span> and <span class="inline text-[1em] leading-7">dihydrotestosterone</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1j1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1k1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1l1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> In doing so, it prevents the effects of these <span class="inline text-[1em] leading-7">hormones</span> in the <span class="inline text-[1em] leading-7">prostate gland</span> and elsewhere in the body.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1r1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1s1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1t1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Apalutamide was first described in 2007<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_21qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup>, and was approved for the treatment of prostate cancer in February 2018.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_41qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_51qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_61qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup> It is the first medication to be approved specifically for the treatment of non-metastatic castration-resistant prostate cancer.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_81qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_91qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup></span>
<h2 id="clinical-data" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Clinical data<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>













































<div class="border-border-l1 overflow-x-auto rounded-lg border my-6 w-full"><table node="[object Object]" class="w-full border-collapse text-sm"><thead node="[object Object]" class="border-border-l1 border-b bg-surface-l1"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Attribute</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Details</span></th></tr></thead><tbody node="[object Object]" class="divide-border-l1 divide-y"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Trade names</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Erleada, others</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Other names</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">ARN-509; JNJ-56021927; JNJ-927; A52</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">AHFS</span><span class="text-[1em] leading-7">/</span><span class="inline text-[1em] leading-7">Drugs.com</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><a href="https://www.drugs.com/monograph/apalutamide.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Monograph</a></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">MedlinePlus</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><a href="https://medlineplus.gov/druginfo/meds/a618018.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">a618018</a></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">License data</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">US </span><span class="inline text-[1em] leading-7">DailyMed</span><span class="text-[1em] leading-7">: </span><a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&amp;query=Erleada" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Erleada</a></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Pregnancy category</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">AU: D</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_kq2qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[10]</sup></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Routes of administration</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">By mouth</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ku2qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Drug class</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Nonsteroidal antiandrogen</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">ATC code</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">L02BB05</span><span class="text-[1em] leading-7"> (</span><a href="https://www.whocc.no/atc_ddd_index/?code=L02BB05" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">WHO</a><span class="text-[1em] leading-7">)</span></td></tr></tbody></table></div>
<h2 id="legal-status" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Legal status<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>













<div class="border-border-l1 overflow-x-auto rounded-lg border my-6 w-full"><table node="[object Object]" class="w-full border-collapse text-sm"><thead node="[object Object]" class="border-border-l1 border-b bg-surface-l1"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Attribute</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Details</span></th></tr></thead><tbody node="[object Object]" class="divide-border-l1 divide-y"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Legal status</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">AU: </span><span class="inline text-[1em] leading-7">S4</span><span class="text-[1em] leading-7"> (Prescription only)</span><br/><span class="text-[1em] leading-7">CA: </span><span class="inline text-[1em] leading-7"> â„ž-only</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_3q3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4a3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4q3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup><br/><span class="text-[1em] leading-7">UK: </span><span class="inline text-[1em] leading-7">POM</span><span class="text-[1em] leading-7"> (Prescription only)</span><br/><span class="text-[1em] leading-7">US: </span><span class="inline text-[1em] leading-7">â„ž-only</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8q3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><br/><span class="text-[1em] leading-7">EU: Rx-only</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_aa3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup><br/><span class="text-[1em] leading-7">In general: â„ž (Prescription only)</span></td></tr></tbody></table></div>
<h2 id="pharmacokinetic-data" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Pharmacokinetic data<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>

































<div class="border-border-l1 overflow-x-auto rounded-lg border my-6 w-full"><table node="[object Object]" class="w-full border-collapse text-sm"><thead node="[object Object]" class="border-border-l1 border-b bg-surface-l1"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Attribute</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Details</span></th></tr></thead><tbody node="[object Object]" class="divide-border-l1 divide-y"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Bioavailability</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">100%</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a64qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Protein binding</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Apalutamide: 96%</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_aa4qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><br/><span class="text-[1em] leading-7">NDMA: 95%</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ma4qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Metabolism</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Liver</span><span class="text-[1em] leading-7"> (</span><span class="inline text-[1em] leading-7">CYP2C8</span><span class="text-[1em] leading-7">, </span><span class="inline text-[1em] leading-7">CYP3A4</span><span class="text-[1em] leading-7">)</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ue4qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Metabolites</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">â€¢ </span><span class="inline text-[1em] leading-7">NDMA</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ei4qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Elimination half-life</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Apalutamide: 3â€“4 days (at </span><span class="inline text-[1em] leading-7">steady-state</span><span class="text-[1em] leading-7">)</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_im4qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[15]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_mm4qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Excretion</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Urine</span><span class="text-[1em] leading-7">: 65%</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_eq4qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><br/><span class="inline text-[1em] leading-7">Feces</span><span class="text-[1em] leading-7">: 24%</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_uq4qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></td></tr></tbody></table></div>
<h2 id="identifiers" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Identifiers<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>

















































<div class="border-border-l1 overflow-x-auto rounded-lg border my-6 w-full"><table node="[object Object]" class="w-full border-collapse text-sm"><thead node="[object Object]" class="border-border-l1 border-b bg-surface-l1"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Attribute</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Details</span></th></tr></thead><tbody node="[object Object]" class="divide-border-l1 divide-y"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">IUPAC name</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">4-[7-[6-cyano-5-(trifluoromethyl)pyridin-3-yl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl]-2-fluoro-</span><em>N</em><span class="text-[1em] leading-7">-methylbenzamide</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">CAS Number</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><a href="https://commonchemistry.cas.org/detail?cas_rn=956104-40-8" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">956104-40-8</a><br/><a href="https://commonchemistry.cas.org/detail?cas_rn=1361232-32-7" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1361232-32-7</a></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">PubChem</span><span class="text-[1em] leading-7"> CID</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><a href="https://pubchem.ncbi.nlm.nih.gov/compound/24872560" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">24872560</a></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">DrugBank</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><a href="https://www.drugbank.ca/drugs/DB11901" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">DB11901</a></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">ChemSpider</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><a href="https://www.chemspider.com/Chemical-Structure.28424131.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">28424131</a></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">UNII</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><a href="https://precision.fda.gov/uniisearch/srs/unii/4T36H88UA7" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">4T36H88UA7</a></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">KEGG</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><a href="https://www.kegg.jp/entry/D11040" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">D11040</a></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">ChEMBL</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><a href="https://www.ebi.ac.uk/chembl/explore/compound/ChEMBL3183409" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">ChEMBL3183409</a></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">CompTox Dashboard</span><span class="text-[1em] leading-7"> (EPA)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><a href="https://comptox.epa.gov/dashboard/chemical/details/DTXSID40241899" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">DTXSID40241899</a></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">ECHA InfoCard</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><a href="https://echa.europa.eu/substance-information/-/substanceinfo/100.235.115" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">100.235.115</a></td></tr></tbody></table></div>
<h2 id="chemical-and-physical-data" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Chemical and physical data<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>

























<div class="border-border-l1 overflow-x-auto rounded-lg border my-6 w-full"><table node="[object Object]" class="w-full border-collapse text-sm"><thead node="[object Object]" class="border-border-l1 border-b bg-surface-l1"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Attribute</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Details</span></th></tr></thead><tbody node="[object Object]" class="divide-border-l1 divide-y"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Formula</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">C21H15F4N5O2S</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Molar mass</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">477.44 gÂ·molâˆ’1</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">SMILES</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">CNC(=O)C1=C(C=C(C=C1)N2C(=S)N(C(=O)C23CCC3)C4=CN=C(C(=C4)C(F)(F)F)C#N)F</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">InChI</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">InChI=1S/C21H15F4N5O2S/c1-27-17(31)13-4-3-11(8-15(13)22)30-19(33)29(18(32)20(30)5-2-6-20)12-7-14(21(23,24)25)16(9-26)28-10-12/h3-4,7-8,10H,2,5-6H2,1H3,(H,27,31)</span><br/><span class="text-[1em] leading-7">Key:HJBWBFZLDZWPHF-UHFFFAOYSA-N</span></td></tr></tbody></table></div>
<h2 id="medical-uses" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Medical uses<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Apalutamide is indicated for the treatment of metastatic castration-sensitive prostate cancer and non-metastatic castration-resistant prostate cancer.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_27qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_37qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Apalutamide is used in conjunction with castration, either via bilateral orchiectomy or gonadotropin-releasing hormone analogue (GnRH analogue) therapy, as a method of androgen deprivation therapy in the treatment of non-metastatic castration-resistant prostate cancer.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_28abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_38abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_48abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_58abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[18]</sup> It is also used in combination with androgen deprivation therapy for the treatment of metastatic castration-sensitive prostate cancer.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_78abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_88abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup></span>
<h2 id="contraindications" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Contraindications<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Apalutamide is contraindicated in females who are or may become pregnant, as it can cause fetal harm and potential loss of pregnancy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_29abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Patients with a history of seizures or conditions predisposing to seizures were excluded from clinical trials due to the risk of seizures, but it is not formally contraindicated; use with caution and discontinue if a seizure occurs.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_29qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></span>
<h2 id="side-effects" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Side effects<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Apalutamide has been found to be well tolerated in clinical trials,<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[19]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_3aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup> with the most common side effects reported when added to surgical or medical castration including fatigue, hypertension, rash, nausea, abdominal pain, and diarrhea.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup> Other side effects have included falls and bone fractures, and hypothyroidism, as well as seizures (in 0.2%), among others.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_aaqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup> Apalutamide is an expected teratogen and has a theoretical risk of birth defects in male infants if taken by women during pregnancy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_caqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> It may impair male fertility.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_eaqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> When used as a monotherapy (i.e., without surgical or medical castration) in men, NSAAs are known to produce additional, estrogenic side effects like breast tenderness, gynecomastia, and feminization in general by increasing estradiol levels.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gaqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[20]</sup> Similarly to the related second-generation NSAA enzalutamide but unlike first-generation NSAAs like flutamide and bicalutamide, elevated liver enzymes and hepatotoxicity have not been reported with apalutamide.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_iaqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> Case reports of rare interstitial lung disease with apalutamide exist similarly to with first-generation NSAAs however.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_kaqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[21]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_laqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_maqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup></span>
<h1 id="overdose" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Overdose<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<span class="mb-4 block break-words text-[1em] leading-7">There is no known <span class="inline text-[1em] leading-7">antidote</span> for <span class="inline text-[1em] leading-7">overdose</span> of apalutamide.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6bqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> General supportive measures should be undertaken until clinical <span class="inline text-[1em] leading-7">toxicity</span>, if any, diminishes or resolves.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_abqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></span>
<h2 id="interactions" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Interactions<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Apalutamide has a high potential for drug interactions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> In terms of effects of apalutamide on other drugs, the exposure of substrates of CYP3A4, CYP2C19, CYP2C9, UDP-glucuronosyltransferase, P-glycoprotein, ABCG2, or OATP1B1 may be reduced to varying extents.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> In terms of effects of other drugs on apalutamide, strong CYP2C8 or CYP3A4 inhibitors may increase levels of apalutamide or its major active metabolite N-desmethylapalutamide, while mild to moderate CYP2C8 or CYP3A4 inhibitors are not expected to affect their exposure.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> Strong CYP2C8 or CYP3A4 inducers may decrease levels of apalutamide and N-desmethylapalutamide, potentially reducing efficacy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[24]</sup></span>
<h1 id="pharmacology" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Pharmacology<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<h2 id="pharmacodynamics" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Pharmacodynamics<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="antiandrogenic-activity" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Antiandrogenic activity<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Apalutamide acts as a <span class="inline text-[1em] leading-7">selective</span> <span class="inline text-[1em] leading-7">competitive</span> <span class="inline text-[1em] leading-7">silent antagonist</span> of the <span class="inline text-[1em] leading-7">androgen receptor</span> (AR), via the <span class="inline text-[1em] leading-7">ligand-binding domain</span>, and hence is an <span class="inline text-[1em] leading-7">antiandrogen</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_eeqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_feqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_geqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_heqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup> It is similar both <span class="inline text-[1em] leading-7">structurally</span> and <span class="inline text-[1em] leading-7">pharmacologically</span> to the <span class="inline text-[1em] leading-7">second-generation NSAA</span> <span class="inline text-[1em] leading-7">enzalutamide</span>,<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_reqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[19]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_seqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> but shows some advantages, including higher antiandrogenic activity as well as several-fold reduced <span class="inline text-[1em] leading-7">central nervous system</span> <span class="inline text-[1em] leading-7">distribution</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_12eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_13eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_14eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup> The latter difference may reduce its comparative risk of <span class="inline text-[1em] leading-7">seizures</span> and other central side effects.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_18eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_19eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1aeqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup> Apalutamide has 5- to 10-fold greater <span class="inline text-[1em] leading-7">affinity</span> for the AR than <span class="inline text-[1em] leading-7">bicalutamide</span>, a <span class="inline text-[1em] leading-7">first-generation NSAA</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1ieqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[18]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1jeqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The acquired F876L mutation of the AR identified in advanced prostate cancer cells has been found to confer resistance to both enzalutamide and apalutamide.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_3fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[27]</sup> A newer NSAA, <span class="inline text-[1em] leading-7">darolutamide</span>, is not affected by this mutation, nor has it been found to be affected by any other tested/well-known AR mutations.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[28]</sup> Apalutamide may be effective in a subset of prostate cancer patients with acquired resistance to <span class="inline text-[1em] leading-7">abiraterone acetate</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_bfabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[19]</sup></span>
<h3 id="other-activities" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Other activities<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Apalutamide shows potent <span class="inline text-[1em] leading-7">induction</span> potential of <span class="inline text-[1em] leading-7">cytochrome P450</span> <span class="inline text-[1em] leading-7">enzymes</span> similarly to enzalutamide.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8gabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9gabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[29]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_agabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[30]</sup> It is a strong inducer of <span class="inline text-[1em] leading-7">CYP3A4</span> and <span class="inline text-[1em] leading-7">CYP2C19</span> and a weak inducer of <span class="inline text-[1em] leading-7">CYP2C9</span>, as well as an inducer of <span class="inline text-[1em] leading-7">UDP-glucuronosyltransferase</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_kgabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> In addition, apalutamide is an inducer of <span class="inline text-[1em] leading-7">P-glycoprotein</span>, <span class="inline text-[1em] leading-7">ABCG2</span>, and <span class="inline text-[1em] leading-7">OATP1B1</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_sgabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Apalutamide binds weakly to and <span class="inline text-[1em] leading-7">inhibits</span> the <span class="inline text-[1em] leading-7">GABAA receptor</span> <em><span class="inline text-[1em] leading-7">in vitro</span></em> similarly to enzalutamide (<span class="inline text-[1em] leading-7">IC50</span> half-maximal inhibitory concentration = 3.0 and 2.7 Î¼M, respectively),<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_agqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> but due to its relatively lower central concentrations, may have a lower risk of <span class="inline text-[1em] leading-7">seizures</span> in comparison.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_egqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_fgqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ggqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[31]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Apalutamide has been found to significantly and concentration-dependently increase <span class="inline text-[1em] leading-7">QT interval</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4habav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></span>
<h2 id="pharmacokinetics" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Pharmacokinetics<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">The mean <span class="inline text-[1em] leading-7">absolute</span> <span class="inline text-[1em] leading-7">oral</span> <span class="inline text-[1em] leading-7">bioavailability</span> of apalutamide is 100%.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8iabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> Mean <span class="inline text-[1em] leading-7">peak levels</span> of apalutamide occur 2 hours following administration, with a range of 1 to 5 hours.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ciabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> Food delays the median time to peak levels of apalutamide by approximately 2 hours, with no significant changes in the peak levels themselves or in <span class="inline text-[1em] leading-7">area-under-curve</span> levels.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_giabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> <span class="inline text-[1em] leading-7">Steady-state</span> levels of apalutamide are achieved following 4 weeks of administration, with an approximate 5-fold accumulation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_kiabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> <span class="inline text-[1em] leading-7">Peak concentrations</span> for 240 mg/day apalutamide at steady-state are 6.0 Î¼g/mL (12.5 Î¼mol/L),<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_oiabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> relative to peak levels of 16.6 Î¼g/mL (35.7 Î¼mol/L) for 160 mg/day <span class="inline text-[1em] leading-7">enzalutamide</span> and mean (<em>R</em>)-bicalutamide levels of 21.6 Î¼g/mL (50.2 Î¼mol/L) for 150 mg/day <span class="inline text-[1em] leading-7">bicalutamide</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_10iabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[32]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_11iabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[33]</sup> The mean <span class="inline text-[1em] leading-7">volume of distribution</span> of apalutamide at steady-state is approximately 276 L.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_15iabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> The <span class="inline text-[1em] leading-7">plasma protein binding</span> of apalutamide is 96%, while that of its major <span class="inline text-[1em] leading-7">metabolite</span> <span class="inline text-[1em] leading-7">N-desmethylapalutamide</span> is 95%, both irrespective of concentration.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1diabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Apalutamide is <span class="inline text-[1em] leading-7">metabolized</span> in the <span class="inline text-[1em] leading-7">liver</span> by <span class="inline text-[1em] leading-7">CYP2C8</span> and <span class="inline text-[1em] leading-7">CYP3A4</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_aiqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> A major <span class="inline text-[1em] leading-7">active metabolite</span>, N-desmethylapalutamide, is formed by these <span class="inline text-[1em] leading-7">enzymes</span>, with similar contribution of each of these enzymes to its formation at steady-state.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_giqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> Following a single oral dose of 200 mg apalutamide, apalutamide represented 45% and N-desmethylapalutamide 44% of total area-under-curve levels.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_iiqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> The mean <span class="inline text-[1em] leading-7">elimination half-life</span> of apalutamide at steady-state is 3 to 4 days.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_miqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_niqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[15]</sup> Fluctuations in apalutamide exposure are low and levels are stable throughout the day, with mean peak-to-trough ratios of 1.63 for apalutamide and 1.27â€“1.3 for N-desmethylapalutamide.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_piqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> After a single dose of apalutamide, its <span class="inline text-[1em] leading-7">clearance</span> rate (CL/F) was 1.3 L/h, while its clearance rate increased to 2.0 L/h at steady-state.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_tiqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup> This change is considered to be likely due to CYP3A4 <span class="inline text-[1em] leading-7">auto-induction</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_11iqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup> Approximately 65% of apalutamide is <span class="inline text-[1em] leading-7">excreted</span> in <span class="inline text-[1em] leading-7">urine</span> (1.2% as unchanged apalutamide and 2.7% as N-desmethylapalutamide) while 24% is excreted in <span class="inline text-[1em] leading-7">feces</span> (1.5% as unchanged apalutamide and 2% as N-desmethylapalutamide).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_19iqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></span>
<h2 id="chemistry" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Chemistry<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Apalutamide is a <span class="inline text-[1em] leading-7">structural analogue</span> of <span class="inline text-[1em] leading-7">enzalutamide</span> and <span class="inline text-[1em] leading-7">RD-162</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8jqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[18]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9jqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[34]</sup> It is a <span class="inline text-[1em] leading-7">pyridyl</span> variant of <span class="inline text-[1em] leading-7">RD-162</span>. Enzalutamide and RD-162 were derived from the <span class="inline text-[1em] leading-7">nonsteroidal androgen</span> <span class="inline text-[1em] leading-7">RU-59063</span>, which itself was derived from the <span class="inline text-[1em] leading-7">first-generation</span> NSAA <span class="inline text-[1em] leading-7">nilutamide</span> and by extension from <span class="inline text-[1em] leading-7">flutamide</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_pjqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[35]</sup></span>
<ul class="marker:text-primary my-4 ml-6 list-disc space-y-2 text-[1em]">
<li class="text-[1em]"><span class="inline text-[1em] leading-7">Flutamide</span></li>
<li class="text-[1em]"><span class="inline text-[1em] leading-7">Nilutamide</span></li>
<li class="text-[1em]"><span class="inline text-[1em] leading-7">RU-59063</span></li>
<li class="text-[1em]"><span class="inline text-[1em] leading-7">Enzalutamide</span></li>
<li class="text-[1em]"><span class="inline text-[1em] leading-7">RD-162</span></li>
<li class="text-[1em]">Apalutamide</li>
</ul>
<h2 id="history" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">History<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Apalutamide was originated by the University of California system and licensed to Aragon Pharmaceuticals, which conducted preclinical development and early clinical trials. In August 2013, Johnson &amp; Johnson acquired Aragon, and Janssen Research &amp; Development, a division of Johnson &amp; Johnson, continued development.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2labav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[36]</sup> It was first described in a 2007 patent application published in November 2007<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4labav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup> and its synthesis in a US patent application filed in March 2009 and published in July 2010.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6labav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[37]</sup> A March 2012 publication described the discovery and development of apalutamide.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8labav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> A phase I clinical trial of apalutamide was completed by March 2012, and the results of this study were published in 2013.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_alabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_blabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[38]</sup> Information on phase III clinical studies, including ATLAS, SPARTAN, and TITAN, was published between 2014 and 2016.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dlabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[39]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_elabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[40]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_flabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[41]</sup> Positive results for phase III trials were first described in 2017, and Janssen submitted a New Drug Application for apalutamide to the United States Food and Drug Administration on 11 October 2017.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hlabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[42]</sup> Apalutamide was approved by the Food and Drug Administration in the United States, under the brand name Erleada, for the treatment of non-metastatic castration-resistant prostate cancer in February 2018.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_jlabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_klabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup> It was subsequently approved in Canada in July 2018, Australia in July 2018, and the European Union in January 2019.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_mlabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[43]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_nlabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup>[new1][new2]</span>
<h2 id="society-and-culture" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Society and culture<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="generic-names" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Generic names<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Apalutamide is the generic name of the medication and its international nonproprietary name.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2mqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[44]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_3mqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[43]</sup> It is also known by its developmental code names ARN-509 and JNJ-56021927.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5mqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[36]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6mqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup></span>
<h3 id="brand-names" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Brand names<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Apalutamide is marketed under the brand names Erleada and Erlyand.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2nqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_3nqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4nqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5nqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[43]</sup></span>
<h3 id="availability" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Availability<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Apalutamide is available in the United States, Canada, the European Union, and Australia.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2oqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_3oqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4oqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5oqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[43]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6oqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup> As of March 2025, a generic version of apalutamide is available in the United States.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8oqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[45]</sup></span></article><div id="references" class="min-w-0 scroll-mt-8 overflow-hidden"><div class="text-[16px]"><h2 id="references" node="[object Object]" class="mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden">References</h2></div><ol class="columns-1 gap-x-12 [counter-reset:item] md:columns-2"><li id="2" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><em><strong>aa</strong></em> <em><strong>ab</strong></em> <em><strong>ac</strong></em> <em><strong>ad</strong></em> <em><strong>ae</strong></em> <em><strong>af</strong></em> <em><strong>ag</strong></em> <em><strong>ah</strong></em> <em><strong>ai</strong></em> <em><strong>aj</strong></em> <em><strong>ak</strong></em> <em><strong>al</strong></em> <em><strong>am</strong></em> <em><strong>an</strong></em> <em><strong>ao</strong></em> <em><strong>ap</strong></em> <em><strong>aq</strong></em> <em><strong>ar</strong></em> <em><strong>as</strong></em> <em><strong>at</strong></em> <em><strong>au</strong></em> <em><strong>av</strong></em> <em><strong>aw</strong></em> <em><strong>ax</strong></em> <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d1cda4f7-cb33-46ea-b9ac-431f6452b1a5" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Erleada- apalutamide tablet, film coated&quot;</a>. <em>DailyMed</em>. 27 October 2020. <a href="https://web.archive.org/web/20201109105822/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d1cda4f7-cb33-46ea-b9ac-431f6452b1a5" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Archived</a> from the original on 9 November 2020. Retrieved 8 November 2020.</span></div></li><li id="8" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://web.archive.org/web/20190423072230/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm596768.htm" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;FDA approves new treatment for a certain type of prostate cancer using novel clinical trial endpoint&quot;</a>. <em><span class="inline text-[1em] leading-7">Food and Drug Administration</span></em> (Press release). 24 March 2020. Archived from <a href="https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm596768.htm" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">the original</a> on 23 April 2019. Retrieved 15 February 2018.</span></div></li><li id="9" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Mulcahy N (14 February 2018). <a href="https://www.medscape.com/viewarticle/892708" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;FDA Approves Apalutamide for Nonmetastatic Prostate Cancer&quot;</a>. <em>Medscape</em>. <a href="https://web.archive.org/web/20201124152424/https://www.medscape.com/viewarticle/892708" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Archived</a> from the original on 24 November 2020. Retrieved 16 August 2024.</span></div></li><li id="10" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Al-Salama ZT (April 2018). &quot;Apalutamide: First Global Approval&quot;. <em>Drugs</em>. <strong>78</strong> (6): 699â€“705. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1007%2Fs40265-018-0900-z" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1007/s40265-018-0900-z</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/29626324" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">29626324</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:4653827" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">4653827</a>.</span></div></li><li id="11" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Schweizer MT, Antonarakis ES (August 2012). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3398601" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born&quot;</a>. <em>Therapeutic Advances in Urology</em>. <strong>4</strong> (4): 167â€“78. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1177%2F1756287212452196" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1177/1756287212452196</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3398601" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">3398601</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/22852027" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">22852027</a>.</span></div></li><li id="12" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Leibowitz-Amit R, Joshua AM (December 2012). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553559" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions&quot;</a>. <em>Current Oncology</em>. <strong>19</strong> (Suppl 3): S22-31. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.3747%2Fco.19.1281" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.3747/co.19.1281</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553559" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">3553559</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/23355790" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">23355790</a>.</span></div></li><li id="13" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Dellis AE, Papatsoris AG (June 2018). &quot;Apalutamide: The established and emerging roles in the treatment of advanced prostate cancer&quot;. <em>Expert Opin Investig Drugs</em>. <strong>27</strong> (6): 553â€“559. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1080%2F13543784.2018.1484107" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1080/13543784.2018.1484107</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/29856649" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">29856649</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:46925616" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">46925616</a>.</span></div></li><li id="14" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, et al. (March 2012). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3306502" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;ARN-509: a novel antiandrogen for prostate cancer treatment&quot;</a>. <em>Cancer Research</em>. <strong>72</strong> (6): 1494â€“503. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1158%2F0008-5472.CAN-11-3948" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1158/0008-5472.CAN-11-3948</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3306502" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">3306502</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/22266222" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">22266222</a>.</span></div></li><li id="15" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://worldwide.espacenet.com/publicationDetails/originalDocument?FT=D&amp;date=20071108&amp;DB=EPODOC&amp;locale=en_EP&amp;CC=WO&amp;NR=2007126765A2&amp;KC=A2&amp;ND=6" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">WO 2007126765</a>, Jung ME, Sawyers CL, Ouk S, Tran C, Wongvipat J, &quot;Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases&quot;, published 8 November 2007, assigned to The Regents Of The University Of California.  <a href="https://web.archive.org/web/20211104133256/https://worldwide.espacenet.com/publicationDetails/originalDocument?FT=D&amp;date=20071108&amp;DB=EPODOC&amp;locale=en_EP&amp;CC=WO&amp;NR=2007126765A2&amp;KC=A2&amp;ND=6" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Archived</a> 4 November 2021 at the <span class="inline text-[1em] leading-7">Wayback Machine</span></span></div></li><li id="1" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.drugs.com/pregnancy/apalutamide.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Apalutamide (Erleada) Use During Pregnancy&quot;</a>. <em>Drugs.com</em>. 20 July 2020. <a href="https://web.archive.org/web/20201129142044/https://www.drugs.com/pregnancy/apalutamide.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Archived</a> from the original on 29 November 2020. Retrieved 28 September 2020.</span></div></li><li id="3" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pdf.hres.ca/dpd_pm/00062050.PDF" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Product monograph including patient medication information&quot;</a> (PDF). Janssen Inc. 6 July 2021. <a href="https://web.archive.org/web/20221103180431/https://pdf.hres.ca/dpd_pm/00062050.PDF" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Archived</a> (PDF) from the original on 3 November 2022. Retrieved 3 November 2022.</span></div></li><li id="4" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://dhpp.hpfb-dgpsa.ca/review-documents/resource/RDS1706106900025" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Regulatory Decision Summary for Erleada&quot;</a>. <em><span class="inline text-[1em] leading-7">Health Canada</span></em>. 2 August 2023. <a href="https://web.archive.org/web/20240402052050/https://dhpp.hpfb-dgpsa.ca/review-documents/resource/RDS1706106900025" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Archived</a> from the original on 2 April 2024. Retrieved 2 April 2024.</span></div></li><li id="5" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/drug-medical-device-highlights-2018.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Drug and medical device highlights 2018: Helping you maintain and improve your health&quot;</a>. <em><span class="inline text-[1em] leading-7">Health Canada</span></em>. 14 October 2020. <a href="https://web.archive.org/web/20240417063539/https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/drug-medical-device-highlights-2018.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Archived</a> from the original on 17 April 2024. Retrieved 17 April 2024.</span></div></li><li id="6" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ema.europa.eu/en/medicines/human/EPAR/erleada" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Erleada EPAR&quot;</a>. <em><span class="inline text-[1em] leading-7">European Medicines Agency</span> (EMA)</em>. 13 November 2018. <a href="https://web.archive.org/web/20201228034526/https://www.ema.europa.eu/en/medicines/human/EPAR/erleada" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Archived</a> from the original on 28 December 2020. Retrieved 9 November 2020.</span></div></li><li id="7" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Rathkopf DE, Morris MJ, Fox JJ, Danila DC, Slovin SF, Hager JH, et al. (October 2013). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782148" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer&quot;</a>. <em>Journal of Clinical Oncology</em>. <strong>31</strong> (28): 3525â€“30. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1200%2FJCO.2013.50.1684" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1200/JCO.2013.50.1684</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782148" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">3782148</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/24002508" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">24002508</a>.</span></div></li><li id="16" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Rathkopf D, Scher HI (2013). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3788593" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Androgen receptor antagonists in castration-resistant prostate cancer&quot;</a>. <em>Cancer Journal</em>. <strong>19</strong> (1): 43â€“9. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1097%2FPPO.0b013e318282635a" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1097/PPO.0b013e318282635a</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3788593" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">3788593</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/23337756" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">23337756</a>.</span></div></li><li id="17" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Kim W, Ryan CJ (February 2015). <a href="https://doi.org/10.1002%2Fcncr.28929" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Quo vadis: advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapies&quot;</a>. <em>Cancer</em>. <strong>121</strong> (3): 361â€“71. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1002%2Fcncr.28929" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1002/cncr.28929</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/25236176" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">25236176</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:6309403" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">6309403</a>.</span></div></li><li id="18" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Kawahara T, Miyamoto H (June 2014). &quot;Androgen Receptor Antagonists in the Treatment of Prostate Cancer&quot;. <em>Clinical Immunology, Endocrine &amp; Metabolic Drugs</em>. <strong>1</strong> (1): 11â€“19. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.2174%2F22127070114019990002" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.2174/22127070114019990002</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/2212-7070" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2212-7070</a>.</span></div></li><li id="19" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Patel JC, Maughan BL, Agarwal AM, Batten JA, Zhang TY, Agarwal N (2013). <a href="https://doi.org/10.1155%2F2013%2F981684" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Emerging molecularly targeted therapies in castration refractory prostate cancer&quot;</a>. <em>Prostate Cancer</em>. <strong>2013</strong> : 981684. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1155%2F2013%2F981684" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1155/2013/981684</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3684034" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">3684034</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/23819055" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">23819055</a>.</span></div></li><li id="21" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Anderson J (March 2003). <a href="https://doi.org/10.1046%2Fj.1464-410x.2003.04026.x" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;The role of antiandrogen monotherapy in the treatment of prostate cancer&quot;</a>. <em>BJU Int</em>. <strong>91</strong> (5): 455â€“61. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1046%2Fj.1464-410x.2003.04026.x" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1046/j.1464-410x.2003.04026.x</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/12603397" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">12603397</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:8639102" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">8639102</a>.</span></div></li><li id="22" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Kirishima F, Shigematsu Y, Kobayashi K (May 2022). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9057741" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Interstitial lung disease induced by apalutamide therapy for castration-resistant prostate cancer: A report of a rare case&quot;</a>. <em>IJU Case Rep</em>. <strong>5</strong> (3): 153â€“155. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1002%2Fiju5.12420" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1002/iju5.12420</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9057741" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">9057741</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/35509772" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">35509772</a>.</span></div></li><li id="23" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Kobe H, Tachikawa R, Masuno Y, Matsunashi A, Murata S, Hagimoto H, et al. (September 2021). &quot;Apalutamide-induced severe interstitial lung disease: A report of two cases from Japan&quot;. <em>Respir Investig</em>. <strong>59</strong> (5): 700â€“705. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fj.resinv.2021.05.006" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/j.resinv.2021.05.006</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/34144936" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">34144936</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:235481675" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">235481675</a>.</span></div></li><li id="24" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Wu B, Shen P, Yin X, Yu L, Wu F, Chen C, et al. (March 2022). &quot;Analysis of adverse event of interstitial lung disease in men with prostate cancer receiving hormone therapy using the Food and Drug Administration Adverse Event Reporting System&quot;. <em>Br J Clin Pharmacol</em>. <strong>89</strong> (2): 440â€“448. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1111%2Fbcp.15336" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1111/bcp.15336</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/35349180" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">35349180</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:247777754" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">247777754</a>.</span></div></li><li id="https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210951s016lbl.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210951s016lbl.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210951s016lbl.pdf</a></span></div></li><li id="25" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Tao YX (11 June 2014). <a href="https://books.google.com/books?id=crNZAwAAQBAJ&amp;pg=PA351" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300"><em>Pharmacology and Therapeutics of Constitutively Active Receptors</em></a>. Elsevier Science. pp. 351â€“. <span class="inline text-[1em] leading-7">ISBN</span> 978-0-12-417206-7. &quot;ARN-509 is related structurally to enzalutamide with greater in vivo activity in CRPC xenograft models (Clegg et al., 2012).&quot;</span></div></li><li id="26" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Joseph JD, Lu N, Qian J, Sensintaffar J, Shao G, Brigham D, et al. (September 2013). <a href="https://doi.org/10.1158%2F2159-8290.CD-13-0226" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509&quot;</a>. <em>Cancer Discovery</em>. <strong>3</strong> (9): 1020â€“9. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1158%2F2159-8290.CD-13-0226" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1158/2159-8290.CD-13-0226</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/23779130" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">23779130</a>.</span></div></li><li id="27" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Nelson WG, Yegnasubramanian S (September 2013). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3800038" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Resistance emerges to second-generation antiandrogens in prostate cancer&quot;</a>. <em>Cancer Discovery</em>. <strong>3</strong> (9): 971â€“4. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1158%2F2159-8290.CD-13-0405" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1158/2159-8290.CD-13-0405</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3800038" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">3800038</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/24019330" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">24019330</a>.</span></div></li><li id="28" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Moilanen AM, Riikonen R, Oksala R, Ravanti L, Aho E, Wohlfahrt G, et al. (July 2015). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490394" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies&quot;</a>. <em>Scientific Reports</em>. <strong>5</strong> 12007. <span class="inline text-[1em] leading-7">Bibcode</span>:<a href="https://ui.adsabs.harvard.edu/abs/2015NatSR...512007M" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2015NatSR...512007M</a>. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1038%2Fsrep12007" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1038/srep12007</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490394" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">4490394</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/26137992" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">26137992</a>.</span></div></li><li id="29" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Fizazi K, Albiges L, Loriot Y, Massard C (2015). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673554" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer&quot;</a>. <em>Expert Review of Anticancer Therapy</em>. <strong>15</strong> (9): 1007â€“17. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1586%2F14737140.2015.1081566" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1586/14737140.2015.1081566</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673554" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">4673554</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/26313416" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">26313416</a>.</span></div></li><li id="30" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Ivachtchenko AV, Mitkin OD, Kudan EV, Rjahovsky AA, Vorobiev AA, Trifelenkov AS, et al. (2014). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3909768" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Preclinical Development of ONC1-13B, Novel Antiandrogen for Prostate Cancer Treatment&quot;</a>. <em>Journal of Cancer</em>. <strong>5</strong> (2): 133â€“42. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.7150%2Fjca.7773" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.7150/jca.7773</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3909768" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">3909768</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/24494031" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">24494031</a>.</span></div></li><li id="20" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Pinto Ã (February 2014). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3928129" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Beyond abiraterone: new hormonal therapies for metastatic castration-resistant prostate cancer&quot;</a>. <em>Cancer Biology &amp; Therapy</em>. <strong>15</strong> (2): 149â€“55. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.4161%2Fcbt.26724" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.4161/cbt.26724</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3928129" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">3928129</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/24100689" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">24100689</a>.</span></div></li><li id="31" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://web.archive.org/web/20210827151554/https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203415s011lbl.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Reference at www.accessdata.fda.gov&quot;</a> (PDF). Archived from <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203415s011lbl.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">the original</a> (PDF) on 27 August 2021. Retrieved 24 February 2018.</span></div></li><li id="32" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Cockshott ID (2004). &quot;Bicalutamide: clinical pharmacokinetics and metabolism&quot;. <em>Clin Pharmacokinet</em>. <strong>43</strong> (13): 855â€“78. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.2165%2F00003088-200443130-00003" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.2165/00003088-200443130-00003</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/15509184" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">15509184</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:29912565" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">29912565</a>.</span></div></li><li id="33" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. (2009). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2981508" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Development of a second-generation antiandrogen for treatment of advanced prostate cancer&quot;</a>. <em>Science</em>. <strong>324</strong> (5928): 787â€“90. <span class="inline text-[1em] leading-7">Bibcode</span>:<a href="https://ui.adsabs.harvard.edu/abs/2009Sci...324..787T" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2009Sci...324..787T</a>. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1126%2Fscience.1168175" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1126/science.1168175</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2981508" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2981508</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/19359544" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">19359544</a>.</span></div></li><li id="34" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Liu B, Su L, Geng J, Liu J, Zhao G (2010). &quot;Developments in nonsteroidal antiandrogens targeting the androgen receptor&quot;. <em>ChemMedChem</em>. <strong>5</strong> (10): 1651â€“61. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1002%2Fcmdc.201000259" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1002/cmdc.201000259</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/20853390" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">20853390</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:23228778" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">23228778</a>.</span></div></li><li id="35" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="http://adisinsight.springer.com/drugs/800032695" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Apalutamide - Janssen Research and Development&quot;</a>. <em>AdisInsight</em>. Springer Nature Switzerland AG. <a href="https://web.archive.org/web/20190103110524/https://adisinsight.springer.com/drugs/800032695" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Archived</a> from the original on 3 January 2019. Retrieved 6 September 2015.</span></div></li><li id="36" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://patents.google.com/patent/US20100190991A1" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">US 20100190991</a>, Ouerfelli O, Dilhas A, Yang G, Zhao H, &quot;Synthesis of thiohydantoins&quot;, issued 11 June 2013, assigned to Sloan Kettering Institute for Cancer Research.  <a href="https://web.archive.org/web/20211105010300/https://patents.google.com/patent/US20100190991A1" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Archived</a> 5 November 2021 at the <span class="inline text-[1em] leading-7">Wayback Machine</span></span></div></li><li id="37" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Rathkopf DE, Morris MJ, Fox JJ, Danila DC, Slovin SF, Hager JH, et al. (October 2013). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782148" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer&quot;</a>. <em>Journal of Clinical Oncology</em>. <strong>31</strong> (28): 3525â€“3530. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1200%2FJCO.2013.50.1684" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1200/JCO.2013.50.1684</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782148" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">3782148</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/24002508" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">24002508</a>.</span></div></li><li id="38" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Smith MR, Liu G, Shreeve SM, Matheny S, Sosa A, Kheoh TS, et al. <em>A randomized double-blind, comparative study of ARN-509 plus androgen deprivation therapy (ADT) versus ADT alone in nonmetastatic castration-resistant prostate cancer (M0-CRPC): The SPARTAN trial</em>. 2014 ASCO Annual Meeting. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1200%2Fjco.2014.32.15_suppl.tps5100" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1200/jco.2014.32.15_suppl.tps5100</a>.</span></div></li><li id="39" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Bossi A, Dearnaley D, McKenzie M, Baskin-Bey E, Tyler R, Tombal B, et al. (2016). <a href="https://doi.org/10.1093%2Fannonc%2Fmdw372.52" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;ATLAS: A phase 3 trial evaluating the efficacy of apalutamide (ARN-509) in patients with high-risk localized or locally advanced prostate cancer receiving primary radiation therapy&quot;</a>. <em>Annals of Oncology</em>. <strong>27</strong> (suppl_6): vi263. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1093%2Fannonc%2Fmdw372.52" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1093/annonc/mdw372.52</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/0923-7534" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">0923-7534</a>.</span></div></li><li id="40" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Chi K, Chowdhury S, Radziszewski P, Lebret T, Ozguroglu M, Sternberg C, et al. (2016). <a href="https://doi.org/10.1093%2Fannonc%2Fmdw372.54" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;TITAN: A randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC)&quot;</a>. <em>Annals of Oncology</em>. <strong>27</strong> (suppl_6): vi265. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1093%2Fannonc%2Fmdw372.54" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1093/annonc/mdw372.54</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/0923-7534" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">0923-7534</a>.<code class="text-fg-solar bg-fg-solar-opaque break-all rounded px-2 align-middle font-mono text-sm" node="[object Object]">{{cite journal}}</code>: CS1 maint: overridden setting (link)</span></div></li><li id="41" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.prnewswire.com/news-releases/janssen-submits-new-drug-application-to-us-fda-for-apalutamide-arn-509-to-treat-men-with-non-metastatic-castration-resistant-prostate-cancer-300534704.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Janssen Submits New Drug Application to U.S. FDA for Apalutamide (ARN-509) to Treat Men with Non-Metastatic Castration-Resistant Prostate Cancer&quot;</a> (Press release). Janssen. <a href="https://web.archive.org/web/20180215084131/https://www.prnewswire.com/news-releases/janssen-submits-new-drug-application-to-us-fda-for-apalutamide-arn-509-to-treat-men-with-non-metastatic-castration-resistant-prostate-cancer-300534704.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Archived</a> from the original on 15 February 2018. Retrieved 15 February 2018 â€“ via PR Newswire.</span></div></li><li id="42" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.drugs.com/monograph/apalutamide.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Apalutamide Monograph for Professionals&quot;</a>. <em>Drugs.com</em>. 10 April 2024. <a href="https://web.archive.org/web/20221210045939/https://www.drugs.com/monograph/apalutamide.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Archived</a> from the original on 10 December 2022. Retrieved 16 August 2024.</span></div></li><li id="43" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">World Health Organization</span> (2016). &quot;International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 75&quot;. <em>WHO Drug Information</em>. <strong>30</strong> (1). <span class="inline text-[1em] leading-7">hdl</span>:<a href="https://hdl.handle.net/10665%2F331046" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10665/331046</a>.</span></div></li><li id="https://www.drugs.com/availability/generic-erleada.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.drugs.com/availability/generic-erleada.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.drugs.com/availability/generic-erleada.html</a></span></div></li></ol></div><div class="text-fg-secondary text-xs [&amp;_*]:mb-2"><hr class="border-border-l1 my-8 rounded-sm border-t"/>
<span class="mb-4 block break-words text-[1em] leading-7">The content is adapted from <a href="https://en.wikipedia.org/wiki/Apalutamide" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Wikipedia</a>, licensed under Creative Commons Attribution-ShareAlike 4.0 License.</span></div></div></div><div class="hidden min-[1400px]:block"></div></div></div><!--$--><!--/$--><div role="region" aria-label="Notifications (F8)" tabindex="-1" style="pointer-events:none"><ol tabindex="-1" class="pointer-events-none fixed top-0 z-[100] flex max-h-screen w-full flex-col-reverse p-4 max-sm:left-0 sm:bottom-0 sm:right-0 sm:top-auto sm:max-w-[420px] sm:flex-col pl-16 pr-2 pt-16 sm:px-4"></ol></div><script type="application/json" id="server-client-data-experimentation">{"status":"uninitialized"}</script><script src="/_next/static/chunks/webpack-e121ed42680f327e.js" nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy" id="_R_" async=""></script><script nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy">(self.__next_f=self.__next_f||[]).push([0])</script><script nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy">self.__next_f.push([1,"1:\"$Sreact.fragment\"\n3:I[91363,[],\"\"]\n4:I[23775,[],\"\"]\n5:I[57654,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"PageHeaderProvider\"]\n6:I[17618,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"HeaderContent\"]\n7:I[25529,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"6751\",\"static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js\"],\"default\"]\n9:I[6666,[],\"OutletBoundary\"]\nb:I[80415,[],\"AsyncMetadataOutlet\"]\nd:I[6666,[],\"ViewportBoundary\"]\nf:I[6666,[],\"MetadataBoundary\"]\n10:\"$Sreact.suspense\"\n12:I[95909,[\"4219\",\"static/chunks/app/global-error-4d07d20223cd4b4c.js\"],\"default\"]\n"])</script><script nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy">self.__next_f.push([1,"13:I[51498,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"ConstantsProvider\"]\n"])</script><script nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy">self.__next_f.push([1,"14:I[91073,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy">self.__next_f.push([1,"15:I[38642,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy">self.__next_f.push([1,"16:I[99648,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy">self.__next_f.push([1,"17:I[78825,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy">self.__next_f.push([1,"18:I[8550,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MixpanelProvider\"]\n"])</script><script nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy">self.__next_f.push([1,"19:I[12290,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MobileTocProvider\"]\n"])</script><script nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy">self.__next_f.push([1,"1a:I[53947,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"NuqsAdapter\"]\n"])</script><script nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy">self.__next_f.push([1,"1b:I[91873,[\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8039\",\"static/chunks/app/error-4a29e9399afba038.js\"],\"default\"]\n1c:I[5091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"4345\",\"static/chunks/app/not-found-dd95690acf732f18.js\"],\"default\"]\n"])</script><script nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy">self.__next_f.push([1,"1d:I[16091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy">self.__next_f.push([1,":HL[\"/_next/static/media/1f2316909698f815.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/3d4419af2cf8609b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/4dec29efcaeb336c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/74452ea3ef0f9101.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/904ef0a86fe32a00.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/d886a03bcda7ad8f.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/e1447589d6f59c4b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/f5a90156f8995c8c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/css/62c4caba71dfda84.css\",\"style\",{\"nonce\":\"MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy\"}]\n:HL[\"/_next/static/css/eb3d87f98fe1565f.css\",\"style\",{\"nonce\":\"MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy\"}]\n:HL[\"/_next/static/css/1b5e561215938d4d.css\",\"style\",{\"nonce\":\"MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy\"}]\n:HL[\"/_next/static/css/0227d069a630d414.css\",\"style\",{\"nonce\":\"MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy\"}]\n:HL[\"/_next/static/css/f87fff2ab93d05a7.css\",\"style\",{\"nonce\":\"MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy\"}]\n"])</script><script nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy">self.__next_f.push([1,"0:{\"P\":null,\"b\":\"BpM29AX4fmgcUxZ_6t0le\",\"p\":\"\",\"c\":[\"\",\"page\",\"Apalutamide\"],\"i\":false,\"f\":[[[\"\",{\"children\":[\"page\",{\"children\":[[\"slug\",\"Apalutamide\",\"d\"],{\"children\":[\"__PAGE__\",{}]}]}]},\"$undefined\",\"$undefined\",true],[\"\",[\"$\",\"$1\",\"c\",{\"children\":[[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/62c4caba71dfda84.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy\"}],[\"$\",\"link\",\"1\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/eb3d87f98fe1565f.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy\"}],[\"$\",\"link\",\"2\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/1b5e561215938d4d.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy\"}],[\"$\",\"link\",\"3\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/0227d069a630d414.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy\"}]],\"$L2\"]}],{\"children\":[\"page\",[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}],{\"children\":[[\"slug\",\"Apalutamide\",\"d\"],[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L5\",null,{\"children\":[[\"$\",\"$L6\",null,{\"maxWidth\":\"full\",\"mobileOptions\":{\"right\":{\"showFixedIssues\":true,\"showThemeSwitcher\":true,\"showSearch\":true,\"showTableOfContents\":true}}}],[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L7\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}]]}],{\"children\":[\"__PAGE__\",[\"$\",\"$1\",\"c\",{\"children\":[\"$L8\",[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/f87fff2ab93d05a7.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy\"}]],[\"$\",\"$L9\",null,{\"children\":[\"$La\",[\"$\",\"$Lb\",null,{\"promise\":\"$@c\"}]]}]]}],{},null,false]},null,false]},null,false]},null,false],[\"$\",\"$1\",\"h\",{\"children\":[null,[[\"$\",\"$Ld\",null,{\"children\":\"$Le\"}],[\"$\",\"meta\",null,{\"name\":\"next-size-adjust\",\"content\":\"\"}]],[\"$\",\"$Lf\",null,{\"children\":[\"$\",\"div\",null,{\"hidden\":true,\"children\":[\"$\",\"$10\",null,{\"fallback\":null,\"children\":\"$L11\"}]}]}]]}],false]],\"m\":\"$undefined\",\"G\":[\"$12\",[]],\"s\":false,\"S\":false}\n"])</script><script nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy">self.__next_f.push([1,"2:[\"$\",\"html\",null,{\"lang\":\"en\",\"className\":\"bg-surface-base antialiased\",\"suppressHydrationWarning\":true,\"children\":[[\"$\",\"head\",null,{\"children\":[[\"$\",\"title\",null,{\"children\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"type\":\"image/x-icon\",\"href\":\"/favicon.ico\",\"sizes\":\"48x48\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-dark.png\",\"media\":\"(prefers-color-scheme: light)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-light.png\",\"media\":\"(prefers-color-scheme: dark)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"apple-touch-icon\",\"href\":\"/icon-192x192.png\"}],[\"$\",\"link\",null,{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\"}],[\"$\",\"meta\",null,{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",null,{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"meta\",null,{\"property\":\"og:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"property\":\"og:url\",\"content\":\"https://grokipedia.com\"}],[\"$\",\"meta\",null,{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:locale\",\"content\":\"en_US\"}],[\"$\",\"meta\",null,{\"property\":\"og:type\",\"content\":\"website\"}],[\"$\",\"meta\",null,{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:alt\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}]]}],[\"$\",\"body\",null,{\"className\":\"flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b\",\"children\":[[\"$\",\"$L13\",null,{\"children\":[\"$\",\"$L14\",null,{\"children\":[\"$\",\"$L15\",null,{\"defaultTheme\":\"dark\",\"nonce\":\"MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy\",\"children\":[\"$\",\"$L16\",null,{\"children\":[\"$\",\"$L17\",null,{\"children\":[\"$\",\"$L18\",null,{\"children\":[\"$\",\"$L19\",null,{\"children\":[\"$\",\"$L1a\",null,{\"children\":[[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$1b\",\"errorStyles\":[],\"errorScripts\":[],\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L1c\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}],[\"$\",\"$L1d\",null,{}]]}]}]}]}]}]}]}]}],[\"$\",\"script\",null,{\"type\":\"application/json\",\"id\":\"server-client-data-experimentation\",\"children\":\"{\\\"status\\\":\\\"uninitialized\\\"}\"}]]}]]}]\n"])</script><script nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy">self.__next_f.push([1,"e:[[\"$\",\"meta\",\"0\",{\"charSet\":\"utf-8\"}],[\"$\",\"meta\",\"1\",{\"name\":\"viewport\",\"content\":\"width=device-width, initial-scale=1, interactive-widget=resizes-content\"}]]\na:null\n"])</script><script nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy">self.__next_f.push([1,"1e:I[42712,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"HydrationBoundary\"]\n"])</script><script nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy">self.__next_f.push([1,"21:I[6367,[],\"IconMark\"]\n1f:T4b73,"])</script><script nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy">self.__next_f.push([1,"# Apalutamide\n\n**Apalutamide** , sold under the brand name **Erleada** among others, is a [nonsteroidal antiandrogen](Nonsteroidal_antiandrogen \"Nonsteroidal antiandrogen\") (NSAA) medication used for the treatment of [prostate cancer](Prostate_cancer \"Prostate cancer\"), including non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC).[2][8][9][8] It is an [androgen receptor](Androgen_receptor \"Androgen receptor\") inhibitor.[2] It is taken [by mouth](Oral_administration \"Oral administration\").[2][10]\n\n[Side effects](Side_effect \"Side effect\") of apalutamide when added to castration include [fatigue](Fatigue_\\(medical\\) \"Fatigue \\(medical\\)\"), [nausea](Nausea \"Nausea\"), [abdominal pain](Abdominal_pain \"Abdominal pain\"), [diarrhea](Diarrhea \"Diarrhea\"), [high blood pressure](Hypertension \"Hypertension\"), [rash](Rash \"Rash\"), [falls](Falling_\\(accident\\) \"Falling \\(accident\\)\"), [bone fractures](Bone_fracture \"Bone fracture\"), and an [underactive thyroid](Hypothyroidism \"Hypothyroidism\").[2][11][12][10][13] Rarely, it can cause [seizures](Seizure \"Seizure\").[2][10] The medication has a high potential for [drug interactions](Drug_interaction \"Drug interaction\").[2][10] Apalutamide is an [antiandrogen](Antiandrogen \"Antiandrogen\"), and acts as an [antagonist](Receptor_antagonist \"Receptor antagonist\") of the [androgen receptor](Androgen_receptor \"Androgen receptor\"), the [biological target](Biological_target \"Biological target\") of [androgens](Androgen \"Androgen\") like [testosterone](Testosterone \"Testosterone\") and [dihydrotestosterone](Dihydrotestosterone \"Dihydrotestosterone\").[2][10][14] In doing so, it prevents the effects of these [hormones](Hormone \"Hormone\") in the [prostate gland](Prostate_gland \"Prostate gland\") and elsewhere in the body.[2][10][14]\n\nApalutamide was first described in 2007[15], and was approved for the treatment of prostate cancer in February 2018.[8][9][10] It is the first medication to be approved specifically for the treatment of non-metastatic castration-resistant prostate cancer.[2][10][9]\n## Clinical data\n\n| Attribute | Details |\n|-----------|---------|\n| [Trade names](Drug_nomenclature#Trade_names \"Drug nomenclature\") | Erleada, others |\n| Other names | ARN-509; JNJ-56021927; JNJ-927; A52 |\n| [AHFS](American_Society_of_Health-System_Pharmacists \"American Society of Health-System Pharmacists\")/[Drugs.com](Drugs.com \"Drugs.com\") | [Monograph](https://www.drugs.com/monograph/apalutamide.html) |\n| [MedlinePlus](MedlinePlus \"MedlinePlus\") | [a618018](https://medlineplus.gov/druginfo/meds/a618018.html) |\n| [License data](Regulation_of_therapeutic_goods \"Regulation of therapeutic goods\") | US [DailyMed](DailyMed \"DailyMed\"): [Erleada](https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all\u0026query=Erleada) |\n| [Pregnancy category](Pregnancy_category \"Pregnancy category\") | AU: D[1] |\n| [Routes of administration](Route_of_administration \"Route of administration\") | [By mouth](Oral_administration \"Oral administration\")[2] |\n| [Drug class](Drug_class \"Drug class\") | [Nonsteroidal antiandrogen](Nonsteroidal_antiandrogen \"Nonsteroidal antiandrogen\") |\n| [ATC code](Anatomical_Therapeutic_Chemical_Classification_System \"Anatomical Therapeutic Chemical Classification System\") | [L02BB05](ATC_code_L02 \"ATC code L02\") ([WHO](https://www.whocc.no/atc_ddd_index/?code=L02BB05)) |\n## Legal status\n\n| Attribute | Details |\n|-----------|---------|\n| [Legal status](Regulation_of_therapeutic_goods \"Regulation of therapeutic goods\") | AU: [S4](Standard_for_the_Uniform_Scheduling_of_Medicines_and_Poisons#Schedule_4 \"Standard for the Uniform Scheduling of Medicines and Poisons\") (Prescription only)\u003cbr\u003eCA: [ â„ž-only](Prescription_drug \"Prescription drug\")[3][4][5]\u003cbr\u003eUK: [POM](Prescription_drug \"Prescription drug\") (Prescription only)\u003cbr\u003eUS: [â„ž-only](Prescription_drug \"Prescription drug\")[2]\u003cbr\u003eEU: Rx-only[6]\u003cbr\u003eIn general: â„ž (Prescription only) |\n## Pharmacokinetic data\n\n| Attribute | Details |\n|-----------|---------|\n| [Bioavailability](Bioavailability \"Bioavailability\") | 100%[2] |\n| [Protein binding](Plasma_protein_binding \"Plasma protein binding\") | Apalutamide: 96%[2]\u003cbr\u003eNDMA: 95%[2] |\n| [Metabolism](Drug_metabolism \"Drug metabolism\") | [Liver](Liver \"Liver\") ([CYP2C8](CYP2C8 \"CYP2C8\"), [CYP3A4](CYP3A4 \"CYP3A4\"))[2] |\n| [Metabolites](Metabolite \"Metabolite\") | â€¢ [NDMA](N-Desmethylapalutamide \"N-Desmethylapalutamide\")[2] |\n| [Elimination half-life](Biological_half-life \"Biological half-life\") | Apalutamide: 3â€“4 days (at [steady-state](Steady_state_\\(pharmacokinetics\\) \"Steady state \\(pharmacokinetics\\)\"))[7][2] |\n| [Excretion](Excretion \"Excretion\") | [Urine](Urine \"Urine\"): 65%[2]\u003cbr\u003e[Feces](Feces \"Feces\"): 24%[2] |\n## Identifiers\n\n| Attribute | Details |\n|-----------|---------|\n| [IUPAC name](IUPAC_nomenclature_of_chemistry \"IUPAC nomenclature of chemistry\") | 4-[7-[6-cyano-5-(trifluoromethyl)pyridin-3-yl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl]-2-fluoro-_N_-methylbenzamide |\n| [CAS Number](CAS_Registry_Number \"CAS Registry Number\") | [956104-40-8](https://commonchemistry.cas.org/detail?cas_rn=956104-40-8)\u003cbr\u003e[1361232-32-7](https://commonchemistry.cas.org/detail?cas_rn=1361232-32-7) |\n| [PubChem](PubChem#CID \"PubChem\") CID | [24872560](https://pubchem.ncbi.nlm.nih.gov/compound/24872560) |\n| [DrugBank](DrugBank \"DrugBank\") | [DB11901](https://www.drugbank.ca/drugs/DB11901) |\n| [ChemSpider](ChemSpider \"ChemSpider\") | [28424131](https://www.chemspider.com/Chemical-Structure.28424131.html) |\n| [UNII](Unique_Ingredient_Identifier \"Unique Ingredient Identifier\") | [4T36H88UA7](https://precision.fda.gov/uniisearch/srs/unii/4T36H88UA7) |\n| [KEGG](KEGG \"KEGG\") | [D11040](https://www.kegg.jp/entry/D11040) |\n| [ChEMBL](ChEMBL \"ChEMBL\") | [ChEMBL3183409](https://www.ebi.ac.uk/chembl/explore/compound/ChEMBL3183409) |\n| [CompTox Dashboard](CompTox_Chemicals_Dashboard \"CompTox Chemicals Dashboard\") (EPA) | [DTXSID40241899](https://comptox.epa.gov/dashboard/chemical/details/DTXSID40241899) |\n| [ECHA InfoCard](ECHA_InfoCard \"ECHA InfoCard\") | [100.235.115](https://echa.europa.eu/substance-information/-/substanceinfo/100.235.115) |\n## Chemical and physical data\n\n| Attribute | Details |\n|-----------|---------|\n| [Formula](Chemical_formula \"Chemical formula\") | C21H15F4N5O2S |\n| [Molar mass](Molar_mass \"Molar mass\") | 477.44 gÂ·molâˆ’1 |\n| [SMILES](Simplified_molecular-input_line-entry_system \"Simplified molecular-input line-entry system\") | CNC(=O)C1=C(C=C(C=C1)N2C(=S)N(C(=O)C23CCC3)C4=CN=C(C(=C4)C(F)(F)F)C#N)F |\n| [InChI](International_Chemical_Identifier \"International Chemical Identifier\") | InChI=1S/C21H15F4N5O2S/c1-27-17(31)13-4-3-11(8-15(13)22)30-19(33)29(18(32)20(30)5-2-6-20)12-7-14(21(23,24)25)16(9-26)28-10-12/h3-4,7-8,10H,2,5-6H2,1H3,(H,27,31)\u003cbr\u003eKey:HJBWBFZLDZWPHF-UHFFFAOYSA-N |\n## Medical uses\n\nApalutamide is indicated for the treatment of metastatic castration-sensitive prostate cancer and non-metastatic castration-resistant prostate cancer.[2][6]\n\nApalutamide is used in conjunction with castration, either via bilateral orchiectomy or gonadotropin-releasing hormone analogue (GnRH analogue) therapy, as a method of androgen deprivation therapy in the treatment of non-metastatic castration-resistant prostate cancer.[2][16][17][18] It is also used in combination with androgen deprivation therapy for the treatment of metastatic castration-sensitive prostate cancer.[2][6]\n## Contraindications\n\nApalutamide is contraindicated in females who are or may become pregnant, as it can cause fetal harm and potential loss of pregnancy.[2]\n\nPatients with a history of seizures or conditions predisposing to seizures were excluded from clinical trials due to the risk of seizures, but it is not formally contraindicated; use with caution and discontinue if a seizure occurs.[2]\n## Side effects\n\nApalutamide has been found to be well tolerated in clinical trials,[19][16] with the most common side effects reported when added to surgical or medical castration including fatigue, hypertension, rash, nausea, abdominal pain, and diarrhea.[2][10] Other side effects have included falls and bone fractures, and hypothyroidism, as well as seizures (in 0.2%), among others.[2][10][9] Apalutamide is an expected teratogen and has a theoretical risk of birth defects in male infants if taken by women during pregnancy.[2] It may impair male fertility.[2] When used as a monotherapy (i.e., without surgical or medical castration) in men, NSAAs are known to produce additional, estrogenic side effects like breast tenderness, gynecomastia, and feminization in general by increasing estradiol levels.[21] Similarly to the related second-generation NSAA enzalutamide but unlike first-generation NSAAs like flutamide and bicalutamide, elevated liver enzymes and hepatotoxicity have not been reported with apalutamide.[2] Case reports of rare interstitial lung disease with apalutamide exist similarly to with first-generation NSAAs however.[22][23][24]\n# Overdose\n\nThere is no known [antidote](Antidote \"Antidote\") for [overdose](Overdose \"Overdose\") of apalutamide.[2] General supportive measures should be undertaken until clinical [toxicity](Toxicity \"Toxicity\"), if any, diminishes or resolves.[2]\n## Interactions\n\nApalutamide has a high potential for drug interactions.[2] In terms of effects of apalutamide on other drugs, the exposure of substrates of CYP3A4, CYP2C19, CYP2C9, UDP-glucuronosyltransferase, P-glycoprotein, ABCG2, or OATP1B1 may be reduced to varying extents.[2] In terms of effects of other drugs on apalutamide, strong CYP2C8 or CYP3A4 inhibitors may increase levels of apalutamide or its major active metabolite N-desmethylapalutamide, while mild to moderate CYP2C8 or CYP3A4 inhibitors are not expected to affect their exposure.[2] Strong CYP2C8 or CYP3A4 inducers may decrease levels of apalutamide and N-desmethylapalutamide, potentially reducing efficacy.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210951s016lbl.pdf)\n# Pharmacology\n\n## Pharmacodynamics\n\n### Antiandrogenic activity\n\nApalutamide acts as a [selective](Binding_selectivity \"Binding selectivity\") [competitive](Competitive_antagonist \"Competitive antagonist\") [silent antagonist](Silent_antagonist \"Silent antagonist\") of the [androgen receptor](Androgen_receptor \"Androgen receptor\") (AR), via the [ligand-binding domain](Ligand-binding_domain \"Ligand-binding domain\"), and hence is an [antiandrogen](Antiandrogen \"Antiandrogen\").[10][14][11][16] It is similar both [structurally](Chemical_structure \"Chemical structure\") and [pharmacologically](Pharmacology \"Pharmacology\") to the [second-generation NSAA](Second-generation_nonsteroidal_antiandrogen \"Second-generation nonsteroidal antiandrogen\") [enzalutamide](Enzalutamide \"Enzalutamide\"),[19][25] but shows some advantages, including higher antiandrogenic activity as well as several-fold reduced [central nervous system](Central_nervous_system \"Central nervous system\") [distribution](Distribution_\\(pharmacology\\) \"Distribution \\(pharmacology\\)\").[14][11][16] The latter difference may reduce its comparative risk of [seizures](Seizure \"Seizure\") and other central side effects.[14][11][16] Apalutamide has 5- to 10-fold greater [affinity](Affinity_\\(pharmacology\\) \"Affinity \\(pharmacology\\)\") for the AR than [bicalutamide](Bicalutamide \"Bicalutamide\"), a [first-generation NSAA](First-generation_nonsteroidal_antiandrogen \"First-generation nonsteroidal antiandrogen\").[18][17]\n\nThe acquired F876L mutation of the AR identified in advanced prostate cancer cells has been found to confer resistance to both enzalutamide and apalutamide.[26][27] A newer NSAA, [darolutamide](Darolutamide \"Darolutamide\"), is not affected by this mutation, nor has it been found to be affected by any other tested/well-known AR mutations.[28] Apalutamide may be effective in a subset of prostate cancer patients with acquired resistance to [abiraterone acetate](Abiraterone_acetate \"Abiraterone acetate\").[19]\n\n### Other activities\n\nApalutamide shows potent [induction](Enzyme_inducer \"Enzyme inducer\") potential of [cytochrome P450](Cytochrome_P450 \"Cytochrome P450\") [enzymes](Enzyme \"Enzyme\") similarly to enzalutamide.[2][29][30] It is a strong inducer of [CYP3A4](CYP3A4 \"CYP3A4\") and [CYP2C19](CYP2C19 \"CYP2C19\") and a weak inducer of [CYP2C9](CYP2C9 \"CYP2C9\"), as well as an inducer of [UDP-glucuronosyltransferase](UDP-glucuronosyltransferase \"UDP-glucuronosyltransferase\").[2] In addition, apalutamide is an inducer of [P-glycoprotein](P-glycoprotein \"P-glycoprotein\"), [ABCG2](ABCG2 \"ABCG2\"), and [OATP1B1](OATP1B1 \"OATP1B1\").[2]\n\nApalutamide binds weakly to and [inhibits](Negative_allosteric_modulator \"Negative allosteric modulator\") the [GABAA receptor](GABAA_receptor \"GABAA receptor\") _[in vitro](In_vitro \"In vitro\")_ similarly to enzalutamide ([IC50](Half-maximal_inhibitory_concentration \"Half-maximal inhibitory concentration\") half-maximal inhibitory concentration = 3.0 and 2.7 Î¼M, respectively),[14] but due to its relatively lower central concentrations, may have a lower risk of [seizures](Seizure \"Seizure\") in comparison.[14][11][20]\n\nApalutamide has been found to significantly and concentration-dependently increase [QT interval](QT_interval \"QT interval\").[2]\n\n## Pharmacokinetics\n\nThe mean [absolute](Absolute_bioavailability \"Absolute bioavailability\") [oral](Oral_administration \"Oral administration\") [bioavailability](Bioavailability \"Bioavailability\") of apalutamide is 100%.[2] Mean [peak levels](Tmax_\\(pharmacology\\) \"Tmax \\(pharmacology\\)\") of apalutamide occur 2 hours following administration, with a range of 1 to 5 hours.[2] Food delays the median time to peak levels of apalutamide by approximately 2 hours, with no significant changes in the peak levels themselves or in [area-under-curve](Area-under-curve_\\(pharmacokinetics\\) \"Area-under-curve \\(pharmacokinetics\\)\") levels.[2] [Steady-state](Steady_state_\\(pharmacokinetics\\) \"Steady state \\(pharmacokinetics\\)\") levels of apalutamide are achieved following 4 weeks of administration, with an approximate 5-fold accumulation.[2] [Peak concentrations](Cmax_\\(pharmacology\\) \"Cmax \\(pharmacology\\)\") for 240 mg/day apalutamide at steady-state are 6.0 Î¼g/mL (12.5 Î¼mol/L),[2] relative to peak levels of 16.6 Î¼g/mL (35.7 Î¼mol/L) for 160 mg/day [enzalutamide](Enzalutamide \"Enzalutamide\") and mean (_R_)-bicalutamide levels of 21.6 Î¼g/mL (50.2 Î¼mol/L) for 150 mg/day [bicalutamide](Bicalutamide \"Bicalutamide\").[31][32] The mean [volume of distribution](Volume_of_distribution \"Volume of distribution\") of apalutamide at steady-state is approximately 276 L.[2] The [plasma protein binding](Plasma_protein_binding \"Plasma protein binding\") of apalutamide is 96%, while that of its major [metabolite](Metabolite \"Metabolite\") [N-desmethylapalutamide](N-desmethylapalutamide \"N-desmethylapalutamide\") is 95%, both irrespective of concentration.[2]\n\nApalutamide is [metabolized](Metabolism \"Metabolism\") in the [liver](Liver \"Liver\") by [CYP2C8](CYP2C8 \"CYP2C8\") and [CYP3A4](CYP3A4 \"CYP3A4\").[2] A major [active metabolite](Active_metabolite \"Active metabolite\"), N-desmethylapalutamide, is formed by these [enzymes](Enzyme \"Enzyme\"), with similar contribution of each of these enzymes to its formation at steady-state.[2] Following a single oral dose of 200 mg apalutamide, apalutamide represented 45% and N-desmethylapalutamide 44% of total area-under-curve levels.[2] The mean [elimination half-life](Elimination_half-life \"Elimination half-life\") of apalutamide at steady-state is 3 to 4 days.[2][7] Fluctuations in apalutamide exposure are low and levels are stable throughout the day, with mean peak-to-trough ratios of 1.63 for apalutamide and 1.27â€“1.3 for N-desmethylapalutamide.[2] After a single dose of apalutamide, its [clearance](Clearance_\\(pharmacology\\) \"Clearance \\(pharmacology\\)\") rate (CL/F) was 1.3 L/h, while its clearance rate increased to 2.0 L/h at steady-state.[10] This change is considered to be likely due to CYP3A4 [auto-induction](Enzyme_induction_and_inhibition \"Enzyme induction and inhibition\").[10] Approximately 65% of apalutamide is [excreted](Excretion \"Excretion\") in [urine](Urine \"Urine\") (1.2% as unchanged apalutamide and 2.7% as N-desmethylapalutamide) while 24% is excreted in [feces](Feces \"Feces\") (1.5% as unchanged apalutamide and 2% as N-desmethylapalutamide).[2]\n## Chemistry\n\nApalutamide is a [structural analogue](Structural_analog \"Structural analog\") of [enzalutamide](Enzalutamide \"Enzalutamide\") and [RD-162](RD-162 \"RD-162\").[18][33] It is a [pyridyl](Pyridine \"Pyridine\") variant of [RD-162](RD-162 \"RD-162\"). Enzalutamide and RD-162 were derived from the [nonsteroidal androgen](Nonsteroidal_androgen \"Nonsteroidal androgen\") [RU-59063](RU-59063 \"RU-59063\"), which itself was derived from the [first-generation](Nonsteroidal_antiandrogen#First-generation \"Nonsteroidal antiandrogen\") NSAA [nilutamide](Nilutamide \"Nilutamide\") and by extension from [flutamide](Flutamide \"Flutamide\").[34]\n\n* [Flutamide](Flutamide \"Flutamide\")\n* [Nilutamide](Nilutamide \"Nilutamide\")\n* [RU-59063](RU-59063 \"RU-59063\")\n* [Enzalutamide](Enzalutamide \"Enzalutamide\")\n* [RD-162](RD-162 \"RD-162\")\n* Apalutamide\n# Apalutamide\n\n## History\n\nApalutamide was originated by the University of California system and licensed to Aragon Pharmaceuticals, which conducted preclinical development and early clinical trials. In August 2013, Johnson \u0026 Johnson acquired Aragon, and Janssen Research \u0026 Development, a division of Johnson \u0026 Johnson, continued development.[35] It was first described in a 2007 patent application published in November 2007[15] and its synthesis in a US patent application filed in March 2009 and published in July 2010.[36] A March 2012 publication described the discovery and development of apalutamide.[14] A phase I clinical trial of apalutamide was completed by March 2012, and the results of this study were published in 2013.[14][37] Information on phase III clinical studies, including ATLAS, SPARTAN, and TITAN, was published between 2014 and 2016.[38][39][40] Positive results for phase III trials were first described in 2017, and Janssen submitted a New Drug Application for apalutamide to the United States Food and Drug Administration on 11 October 2017.[41] Apalutamide was approved by the Food and Drug Administration in the United States, under the brand name Erleada, for the treatment of non-metastatic castration-resistant prostate cancer in February 2018.[8][9] It was subsequently approved in Canada in July 2018, Australia in July 2018, and the European Union in January 2019.[42][6][new1][new2]\n## Society and culture\n\n### Generic names\n\nApalutamide is the generic name of the medication and its international nonproprietary name.[43][42] It is also known by its developmental code names ARN-509 and JNJ-56021927.[35][10]\n\n### Brand names\n\nApalutamide is marketed under the brand names Erleada and Erlyand.[2][8][9][42]\n\n### Availability\n\nApalutamide is available in the United States, Canada, the European Union, and Australia.[2][8][9][42][6] As of March 2025, a generic version of apalutamide is available in the United States.[](https://www.drugs.com/availability/generic-erleada.html)"])</script><script nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy">self.__next_f.push([1,"8:[\"$\",\"$L1e\",null,{\"state\":{\"mutations\":[],\"queries\":[{\"dehydratedAt\":1761883424118,\"state\":{\"data\":{\"page\":{\"citations\":[{\"id\":\"1\",\"title\":\"** [\\\"Apalutamide (Erleada) Use During Pregnancy\\\"](https://www.drugs.com/pregnancy/apalutamide.html). _Drugs.com_. 20 July 2020. [Archived](https://web.archive.org/web/20201129142044/https://www.drugs.com/pregnancy/apalutamide.html) from the original on 29 November 2020. Retrieved 28 September 2020.\",\"description\":\"1. **^** [\\\"Apalutamide (Erleada) Use During Pregnancy\\\"](https://www.drugs.com/pregnancy/apalutamide.html). _Drugs.com_. 20 July 2020. [Archived](https://web.archive.org/web/20201129142044/https://www.drugs.com/pregnancy/apalutamide.html) from the original on 29 November 2020. Retrieved 28 September 2020.\",\"url\":\"https://www.drugs.com/pregnancy/apalutamide.html\",\"favicon\":\"\"},{\"id\":\"2\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ _**h**_ _**i**_ _**j**_ _**k**_ _**l**_ _**m**_ _**n**_ _**o**_ _**p**_ _**q**_ _**r**_ _**s**_ _**t**_ _**u**_ _**v**_ _**w**_ _**x**_ _**y**_ _**z**_ _**aa**_ _**ab**_ _**ac**_ _**ad**_ _**ae**_ _**af**_ _**ag**_ _**ah**_ _**ai**_ _**aj**_ _**ak**_ _**al**_ _**am**_ _**an**_ _**ao**_ _**ap**_ _**aq**_ _**ar**_ _**as**_ _**at**_ _**au**_ _**av**_ _**aw**_ _**ax**_ [\\\"Erleada- apalutamide tablet, film coated\\\"](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d1cda4f7-cb33-46ea-b9ac-431f6452b1a5). _DailyMed_. 27 October 2020. [Archived](https://web.archive.org/web/20201109105822/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d1cda4f7-cb33-46ea-b9ac-431f6452b1a5) from the original on 9 November 2020. Retrieved 8 November 2020.\",\"description\":\"2. ^ _**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ _**h**_ _**i**_ _**j**_ _**k**_ _**l**_ _**m**_ _**n**_ _**o**_ _**p**_ _**q**_ _**r**_ _**s**_ _**t**_ _**u**_ _**v**_ _**w**_ _**x**_ _**y**_ _**z**_ _**aa**_ _**ab**_ _**ac**_ _**ad**_ _**ae**_ _**af**_ _**ag**_ _**ah**_ _**ai**_ _**aj**_ _**ak**_ _**al**_ _**am**_ _**an**_ _**ao**_ _**ap**_ _**aq**_ _**ar**_ _**as**_ _**at**_ _**au**_ _**av**_ _**aw**_ _**ax**_ [\\\"Erleada- apalutamide tablet, film coated\\\"](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d1cda4f7-cb33-46ea-b9ac-431f6452b1a5). _DailyMed_. 27 October 2020. [Archived](https://web.archive.org/web/20201109105822/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d1cda4f7-cb33-46ea-b9ac-431f6452b1a5) from the original on 9 November 2020. Retrieved 8 November 2020.\",\"url\":\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d1cda4f7-cb33-46ea-b9ac-431f6452b1a5\",\"favicon\":\"\"},{\"id\":\"3\",\"title\":\"** [\\\"Product monograph including patient medication information\\\"](https://pdf.hres.ca/dpd_pm/00062050.PDF) (PDF). Janssen Inc. 6 July 2021. [Archived](https://web.archive.org/web/20221103180431/https://pdf.hres.ca/dpd_pm/00062050.PDF) (PDF) from the original on 3 November 2022. Retrieved 3 November 2022.\",\"description\":\"3. **^** [\\\"Product monograph including patient medication information\\\"](https://pdf.hres.ca/dpd_pm/00062050.PDF) (PDF). Janssen Inc. 6 July 2021. [Archived](https://web.archive.org/web/20221103180431/https://pdf.hres.ca/dpd_pm/00062050.PDF) (PDF) from the original on 3 November 2022. Retrieved 3 November 2022.\",\"url\":\"https://pdf.hres.ca/dpd_pm/00062050.PDF\",\"favicon\":\"\"},{\"id\":\"4\",\"title\":\"** [\\\"Regulatory Decision Summary for Erleada\\\"](https://dhpp.hpfb-dgpsa.ca/review-documents/resource/RDS1706106900025). _[Health Canada](Health_Canada \\\"Health Canada\\\")_. 2 August 2023. [Archived](https://web.archive.org/web/20240402052050/https://dhpp.hpfb-dgpsa.ca/review-documents/resource/RDS1706106900025) from the original on 2 April 2024. Retrieved 2 April 2024.\",\"description\":\"4. **^** [\\\"Regulatory Decision Summary for Erleada\\\"](https://dhpp.hpfb-dgpsa.ca/review-documents/resource/RDS1706106900025). _[Health Canada](Health_Canada \\\"Health Canada\\\")_. 2 August 2023. [Archived](https://web.archive.org/web/20240402052050/https://dhpp.hpfb-dgpsa.ca/review-documents/resource/RDS1706106900025) from the original on 2 April 2024. Retrieved 2 April 2024.\",\"url\":\"https://dhpp.hpfb-dgpsa.ca/review-documents/resource/RDS1706106900025\",\"favicon\":\"\"},{\"id\":\"5\",\"title\":\"** [\\\"Drug and medical device highlights 2018: Helping you maintain and improve your health\\\"](https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/drug-medical-device-highlights-2018.html). _[Health Canada](Health_Canada \\\"Health Canada\\\")_. 14 October 2020. [Archived](https://web.archive.org/web/20240417063539/https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/drug-medical-device-highlights-2018.html) from the original on 17 April 2024. Retrieved 17 April 2024.\",\"description\":\"5. **^** [\\\"Drug and medical device highlights 2018: Helping you maintain and improve your health\\\"](https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/drug-medical-device-highlights-2018.html). _[Health Canada](Health_Canada \\\"Health Canada\\\")_. 14 October 2020. [Archived](https://web.archive.org/web/20240417063539/https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/drug-medical-device-highlights-2018.html) from the original on 17 April 2024. Retrieved 17 April 2024.\",\"url\":\"https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/drug-medical-device-highlights-2018.html\",\"favicon\":\"\"},{\"id\":\"6\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ [\\\"Erleada EPAR\\\"](https://www.ema.europa.eu/en/medicines/human/EPAR/erleada). _[European Medicines Agency](European_Medicines_Agency \\\"European Medicines Agency\\\") (EMA)_. 13 November 2018. [Archived](https://web.archive.org/web/20201228034526/https://www.ema.europa.eu/en/medicines/human/EPAR/erleada) from the original on 28 December 2020. Retrieved 9 November 2020.\",\"description\":\"6. ^ _**a**_ _**b**_ _**c**_ _**d**_ [\\\"Erleada EPAR\\\"](https://www.ema.europa.eu/en/medicines/human/EPAR/erleada). _[European Medicines Agency](European_Medicines_Agency \\\"European Medicines Agency\\\") (EMA)_. 13 November 2018. [Archived](https://web.archive.org/web/20201228034526/https://www.ema.europa.eu/en/medicines/human/EPAR/erleada) from the original on 28 December 2020. Retrieved 9 November 2020.\",\"url\":\"https://www.ema.europa.eu/en/medicines/human/EPAR/erleada\",\"favicon\":\"\"},{\"id\":\"7\",\"title\":\"_**a**_ _**b**_ Rathkopf DE, Morris MJ, Fox JJ, Danila DC, Slovin SF, Hager JH, et al. (October 2013). [\\\"Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782148). _Journal of Clinical Oncology_. **31** (28): 3525â€“30\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1200/JCO.2013.50.1684](https://doi.org/10.1200%2FJCO.2013.50.1684). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3782148](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782148). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [24002508](https://pubmed.ncbi.nlm.nih.gov/24002508).\",\"description\":\"7. ^ _**a**_ _**b**_ Rathkopf DE, Morris MJ, Fox JJ, Danila DC, Slovin SF, Hager JH, et al. (October 2013). [\\\"Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782148). _Journal of Clinical Oncology_. **31** (28): 3525â€“30\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1200/JCO.2013.50.1684](https://doi.org/10.1200%2FJCO.2013.50.1684). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3782148](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782148). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [24002508](https://pubmed.ncbi.nlm.nih.gov/24002508).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782148\",\"favicon\":\"\"},{\"id\":\"8\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ _**e**_ [\\\"FDA approves new treatment for a certain type of prostate cancer using novel clinical trial endpoint\\\"](https://web.archive.org/web/20190423072230/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm596768.htm). _[Food and Drug Administration](Food_and_Drug_Administration \\\"Food and Drug Administration\\\")_ (Press release). 24 March 2020. Archived from [the original](https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm596768.htm) on 23 April 2019. Retrieved 15 February 2018.\",\"description\":\"8. ^ _**a**_ _**b**_ _**c**_ _**d**_ _**e**_ [\\\"FDA approves new treatment for a certain type of prostate cancer using novel clinical trial endpoint\\\"](https://web.archive.org/web/20190423072230/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm596768.htm). _[Food and Drug Administration](Food_and_Drug_Administration \\\"Food and Drug Administration\\\")_ (Press release). 24 March 2020. Archived from [the original](https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm596768.htm) on 23 April 2019. Retrieved 15 February 2018.\",\"url\":\"https://web.archive.org/web/20190423072230/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm596768.htm\",\"favicon\":\"\"},{\"id\":\"9\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ Mulcahy N (14 February 2018). [\\\"FDA Approves Apalutamide for Nonmetastatic Prostate Cancer\\\"](https://www.medscape.com/viewarticle/892708). _Medscape_. [Archived](https://web.archive.org/web/20201124152424/https://www.medscape.com/viewarticle/892708) from the original on 24 November 2020. Retrieved 16 August 2024.\",\"description\":\"9. ^ _**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ Mulcahy N (14 February 2018). [\\\"FDA Approves Apalutamide for Nonmetastatic Prostate Cancer\\\"](https://www.medscape.com/viewarticle/892708). _Medscape_. [Archived](https://web.archive.org/web/20201124152424/https://www.medscape.com/viewarticle/892708) from the original on 24 November 2020. Retrieved 16 August 2024.\",\"url\":\"https://www.medscape.com/viewarticle/892708\",\"favicon\":\"\"},{\"id\":\"10\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ _**h**_ _**i**_ _**j**_ _**k**_ _**l**_ _**m**_ Al-Salama ZT (April 2018). \\\"Apalutamide: First Global Approval\\\". _Drugs_. **78** (6): 699â€“705\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1007/s40265-018-0900-z](https://doi.org/10.1007%2Fs40265-018-0900-z). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [29626324](https://pubmed.ncbi.nlm.nih.gov/29626324). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [4653827](https://api.semanticscholar.org/CorpusID:4653827).\",\"description\":\"10. ^ _**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ _**h**_ _**i**_ _**j**_ _**k**_ _**l**_ _**m**_ Al-Salama ZT (April 2018). \\\"Apalutamide: First Global Approval\\\". _Drugs_. **78** (6): 699â€“705\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1007/s40265-018-0900-z](https://doi.org/10.1007%2Fs40265-018-0900-z). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [29626324](https://pubmed.ncbi.nlm.nih.gov/29626324). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [4653827](https://api.semanticscholar.org/CorpusID:4653827).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"11\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ Schweizer MT, Antonarakis ES (August 2012). [\\\"Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3398601). _Therapeutic Advances in Urology_. **4** (4): 167â€“78\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1177/1756287212452196](https://doi.org/10.1177%2F1756287212452196). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3398601](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3398601). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22852027](https://pubmed.ncbi.nlm.nih.gov/22852027).\",\"description\":\"11. ^ _**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ Schweizer MT, Antonarakis ES (August 2012). [\\\"Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3398601). _Therapeutic Advances in Urology_. **4** (4): 167â€“78\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1177/1756287212452196](https://doi.org/10.1177%2F1756287212452196). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3398601](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3398601). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22852027](https://pubmed.ncbi.nlm.nih.gov/22852027).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3398601\",\"favicon\":\"\"},{\"id\":\"12\",\"title\":\"_**a**_ _**b**_ Leibowitz-Amit R, Joshua AM (December 2012). [\\\"Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553559). _Current Oncology_. **19** (Suppl 3): S22-31. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.3747/co.19.1281](https://doi.org/10.3747%2Fco.19.1281). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3553559](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553559). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [23355790](https://pubmed.ncbi.nlm.nih.gov/23355790).\",\"description\":\"12. ^ _**a**_ _**b**_ Leibowitz-Amit R, Joshua AM (December 2012). [\\\"Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553559). _Current Oncology_. **19** (Suppl 3): S22-31. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.3747/co.19.1281](https://doi.org/10.3747%2Fco.19.1281). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3553559](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553559). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [23355790](https://pubmed.ncbi.nlm.nih.gov/23355790).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553559\",\"favicon\":\"\"},{\"id\":\"13\",\"title\":\"_**a**_ _**b**_ Dellis AE, Papatsoris AG (June 2018). \\\"Apalutamide: The established and emerging roles in the treatment of advanced prostate cancer\\\". _Expert Opin Investig Drugs_. **27** (6): 553â€“559\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1080/13543784.2018.1484107](https://doi.org/10.1080%2F13543784.2018.1484107). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [29856649](https://pubmed.ncbi.nlm.nih.gov/29856649). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [46925616](https://api.semanticscholar.org/CorpusID:46925616).\",\"description\":\"13. ^ _**a**_ _**b**_ Dellis AE, Papatsoris AG (June 2018). \\\"Apalutamide: The established and emerging roles in the treatment of advanced prostate cancer\\\". _Expert Opin Investig Drugs_. **27** (6): 553â€“559\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1080/13543784.2018.1484107](https://doi.org/10.1080%2F13543784.2018.1484107). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [29856649](https://pubmed.ncbi.nlm.nih.gov/29856649). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [46925616](https://api.semanticscholar.org/CorpusID:46925616).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"14\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ _**h**_ _**i**_ Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, et al. (March 2012). [\\\"ARN-509: a novel antiandrogen for prostate cancer treatment\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3306502). _Cancer Research_. **72** (6): 1494â€“503\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1158/0008-5472.CAN-11-3948](https://doi.org/10.1158%2F0008-5472.CAN-11-3948). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3306502](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3306502). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22266222](https://pubmed.ncbi.nlm.nih.gov/22266222).\",\"description\":\"14. ^ _**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ _**h**_ _**i**_ Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, et al. (March 2012). [\\\"ARN-509: a novel antiandrogen for prostate cancer treatment\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3306502). _Cancer Research_. **72** (6): 1494â€“503\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1158/0008-5472.CAN-11-3948](https://doi.org/10.1158%2F0008-5472.CAN-11-3948). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3306502](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3306502). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22266222](https://pubmed.ncbi.nlm.nih.gov/22266222).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3306502\",\"favicon\":\"\"},{\"id\":\"15\",\"title\":\"_**a**_ _**b**_ [WO 2007126765](https://worldwide.espacenet.com/publicationDetails/originalDocument?FT=D\u0026date=20071108\u0026DB=EPODOC\u0026locale=en_EP\u0026CC=WO\u0026NR=2007126765A2\u0026KC=A2\u0026ND=6), Jung ME, Sawyers CL, Ouk S, Tran C, Wongvipat J, \\\"Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases\\\", published 8 November 2007, assigned to The Regents Of The University Of California.  [Archived](https://web.archive.org/web/20211104133256/https://worldwide.espacenet.com/publicationDetails/originalDocument?FT=D\u0026date=20071108\u0026DB=EPODOC\u0026locale=en_EP\u0026CC=WO\u0026NR=2007126765A2\u0026KC=A2\u0026ND=6) 4 November 2021 at the [Wayback Machine](Wayback_Machine \\\"Wayback Machine\\\")\",\"description\":\"15. ^ _**a**_ _**b**_ [WO 2007126765](https://worldwide.espacenet.com/publicationDetails/originalDocument?FT=D\u0026date=20071108\u0026DB=EPODOC\u0026locale=en_EP\u0026CC=WO\u0026NR=2007126765A2\u0026KC=A2\u0026ND=6), Jung ME, Sawyers CL, Ouk S, Tran C, Wongvipat J, \\\"Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases\\\", published 8 November 2007, assigned to The Regents Of The University Of California.  [Archived](https://web.archive.org/web/20211104133256/https://worldwide.espacenet.com/publicationDetails/originalDocument?FT=D\u0026date=20071108\u0026DB=EPODOC\u0026locale=en_EP\u0026CC=WO\u0026NR=2007126765A2\u0026KC=A2\u0026ND=6) 4 November 2021 at the [Wayback Machine](Wayback_Machine \\\"Wayback Machine\\\")\",\"url\":\"https://worldwide.espacenet.com/publicationDetails/originalDocument?FT=D\u0026date=20071108\u0026DB=EPODOC\u0026locale=en_EP\u0026CC=WO\u0026NR=2007126765A2\u0026KC=A2\u0026ND=6\",\"favicon\":\"\"},{\"id\":\"16\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ _**e**_ Rathkopf D, Scher HI (2013). [\\\"Androgen receptor antagonists in castration-resistant prostate cancer\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3788593). _Cancer Journal_. **19** (1): 43â€“9\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1097/PPO.0b013e318282635a](https://doi.org/10.1097%2FPPO.0b013e318282635a). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3788593](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3788593). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [23337756](https://pubmed.ncbi.nlm.nih.gov/23337756).\",\"description\":\"16. ^ _**a**_ _**b**_ _**c**_ _**d**_ _**e**_ Rathkopf D, Scher HI (2013). [\\\"Androgen receptor antagonists in castration-resistant prostate cancer\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3788593). _Cancer Journal_. **19** (1): 43â€“9\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1097/PPO.0b013e318282635a](https://doi.org/10.1097%2FPPO.0b013e318282635a). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3788593](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3788593). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [23337756](https://pubmed.ncbi.nlm.nih.gov/23337756).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3788593\",\"favicon\":\"\"},{\"id\":\"17\",\"title\":\"_**a**_ _**b**_ Kim W, Ryan CJ (February 2015). [\\\"Quo vadis: advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapies\\\"](https://doi.org/10.1002%2Fcncr.28929). _Cancer_. **121** (3): 361â€“71\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1002/cncr.28929](https://doi.org/10.1002%2Fcncr.28929). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [25236176](https://pubmed.ncbi.nlm.nih.gov/25236176). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [6309403](https://api.semanticscholar.org/CorpusID:6309403).\",\"description\":\"17. ^ _**a**_ _**b**_ Kim W, Ryan CJ (February 2015). [\\\"Quo vadis: advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapies\\\"](https://doi.org/10.1002%2Fcncr.28929). _Cancer_. **121** (3): 361â€“71\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1002/cncr.28929](https://doi.org/10.1002%2Fcncr.28929). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [25236176](https://pubmed.ncbi.nlm.nih.gov/25236176). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [6309403](https://api.semanticscholar.org/CorpusID:6309403).\",\"url\":\"https://doi.org/10.1002%2Fcncr.28929\",\"favicon\":\"\"},{\"id\":\"18\",\"title\":\"_**a**_ _**b**_ _**c**_ Kawahara T, Miyamoto H (June 2014). \\\"Androgen Receptor Antagonists in the Treatment of Prostate Cancer\\\". _Clinical Immunology, Endocrine \u0026 Metabolic Drugs_. **1** (1): 11â€“19\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.2174/22127070114019990002](https://doi.org/10.2174%2F22127070114019990002). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [2212-7070](https://search.worldcat.org/issn/2212-7070).\",\"description\":\"18. ^ _**a**_ _**b**_ _**c**_ Kawahara T, Miyamoto H (June 2014). \\\"Androgen Receptor Antagonists in the Treatment of Prostate Cancer\\\". _Clinical Immunology, Endocrine \u0026 Metabolic Drugs_. **1** (1): 11â€“19\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.2174/22127070114019990002](https://doi.org/10.2174%2F22127070114019990002). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [2212-7070](https://search.worldcat.org/issn/2212-7070).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"19\",\"title\":\"_**a**_ _**b**_ _**c**_ Patel JC, Maughan BL, Agarwal AM, Batten JA, Zhang TY, Agarwal N (2013). [\\\"Emerging molecularly targeted therapies in castration refractory prostate cancer\\\"](https://doi.org/10.1155%2F2013%2F981684). _Prostate Cancer_. **2013** : 981684. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1155/2013/981684](https://doi.org/10.1155%2F2013%2F981684). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3684034](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3684034). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [23819055](https://pubmed.ncbi.nlm.nih.gov/23819055).\",\"description\":\"19. ^ _**a**_ _**b**_ _**c**_ Patel JC, Maughan BL, Agarwal AM, Batten JA, Zhang TY, Agarwal N (2013). [\\\"Emerging molecularly targeted therapies in castration refractory prostate cancer\\\"](https://doi.org/10.1155%2F2013%2F981684). _Prostate Cancer_. **2013** : 981684. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1155/2013/981684](https://doi.org/10.1155%2F2013%2F981684). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3684034](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3684034). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [23819055](https://pubmed.ncbi.nlm.nih.gov/23819055).\",\"url\":\"https://doi.org/10.1155%2F2013%2F981684\",\"favicon\":\"\"},{\"id\":\"20\",\"title\":\"_**a**_ _**b**_ Pinto Ã (February 2014). [\\\"Beyond abiraterone: new hormonal therapies for metastatic castration-resistant prostate cancer\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3928129). _Cancer Biology \u0026 Therapy_. **15** (2): 149â€“55\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.4161/cbt.26724](https://doi.org/10.4161%2Fcbt.26724). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3928129](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3928129). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [24100689](https://pubmed.ncbi.nlm.nih.gov/24100689).\",\"description\":\"20. ^ _**a**_ _**b**_ Pinto Ã (February 2014). [\\\"Beyond abiraterone: new hormonal therapies for metastatic castration-resistant prostate cancer\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3928129). _Cancer Biology \u0026 Therapy_. **15** (2): 149â€“55\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.4161/cbt.26724](https://doi.org/10.4161%2Fcbt.26724). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3928129](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3928129). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [24100689](https://pubmed.ncbi.nlm.nih.gov/24100689).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3928129\",\"favicon\":\"\"},{\"id\":\"21\",\"title\":\"** Anderson J (March 2003). [\\\"The role of antiandrogen monotherapy in the treatment of prostate cancer\\\"](https://doi.org/10.1046%2Fj.1464-410x.2003.04026.x). _BJU Int_. **91** (5): 455â€“61\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1046/j.1464-410x.2003.04026.x](https://doi.org/10.1046%2Fj.1464-410x.2003.04026.x). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [12603397](https://pubmed.ncbi.nlm.nih.gov/12603397). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [8639102](https://api.semanticscholar.org/CorpusID:8639102).\",\"description\":\"21. **^** Anderson J (March 2003). [\\\"The role of antiandrogen monotherapy in the treatment of prostate cancer\\\"](https://doi.org/10.1046%2Fj.1464-410x.2003.04026.x). _BJU Int_. **91** (5): 455â€“61\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1046/j.1464-410x.2003.04026.x](https://doi.org/10.1046%2Fj.1464-410x.2003.04026.x). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [12603397](https://pubmed.ncbi.nlm.nih.gov/12603397). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [8639102](https://api.semanticscholar.org/CorpusID:8639102).\",\"url\":\"https://doi.org/10.1046%2Fj.1464-410x.2003.04026.x\",\"favicon\":\"\"},{\"id\":\"22\",\"title\":\"** Kirishima F, Shigematsu Y, Kobayashi K (May 2022). [\\\"Interstitial lung disease induced by apalutamide therapy for castration-resistant prostate cancer: A report of a rare case\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9057741). _IJU Case Rep_. **5** (3): 153â€“155\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1002/iju5.12420](https://doi.org/10.1002%2Fiju5.12420). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [9057741](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9057741). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [35509772](https://pubmed.ncbi.nlm.nih.gov/35509772).\",\"description\":\"22. **^** Kirishima F, Shigematsu Y, Kobayashi K (May 2022). [\\\"Interstitial lung disease induced by apalutamide therapy for castration-resistant prostate cancer: A report of a rare case\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9057741). _IJU Case Rep_. **5** (3): 153â€“155\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1002/iju5.12420](https://doi.org/10.1002%2Fiju5.12420). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [9057741](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9057741). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [35509772](https://pubmed.ncbi.nlm.nih.gov/35509772).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9057741\",\"favicon\":\"\"},{\"id\":\"23\",\"title\":\"** Kobe H, Tachikawa R, Masuno Y, Matsunashi A, Murata S, Hagimoto H, et al. (September 2021). \\\"Apalutamide-induced severe interstitial lung disease: A report of two cases from Japan\\\". _Respir Investig_. **59** (5): 700â€“705\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.resinv.2021.05.006](https://doi.org/10.1016%2Fj.resinv.2021.05.006). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [34144936](https://pubmed.ncbi.nlm.nih.gov/34144936). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [235481675](https://api.semanticscholar.org/CorpusID:235481675).\",\"description\":\"23. **^** Kobe H, Tachikawa R, Masuno Y, Matsunashi A, Murata S, Hagimoto H, et al. (September 2021). \\\"Apalutamide-induced severe interstitial lung disease: A report of two cases from Japan\\\". _Respir Investig_. **59** (5): 700â€“705\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.resinv.2021.05.006](https://doi.org/10.1016%2Fj.resinv.2021.05.006). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [34144936](https://pubmed.ncbi.nlm.nih.gov/34144936). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [235481675](https://api.semanticscholar.org/CorpusID:235481675).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"24\",\"title\":\"** Wu B, Shen P, Yin X, Yu L, Wu F, Chen C, et al. (March 2022). \\\"Analysis of adverse event of interstitial lung disease in men with prostate cancer receiving hormone therapy using the Food and Drug Administration Adverse Event Reporting System\\\". _Br J Clin Pharmacol_. **89** (2): 440â€“448\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1111/bcp.15336](https://doi.org/10.1111%2Fbcp.15336). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [35349180](https://pubmed.ncbi.nlm.nih.gov/35349180). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [247777754](https://api.semanticscholar.org/CorpusID:247777754).\",\"description\":\"24. **^** Wu B, Shen P, Yin X, Yu L, Wu F, Chen C, et al. (March 2022). \\\"Analysis of adverse event of interstitial lung disease in men with prostate cancer receiving hormone therapy using the Food and Drug Administration Adverse Event Reporting System\\\". _Br J Clin Pharmacol_. **89** (2): 440â€“448\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1111/bcp.15336](https://doi.org/10.1111%2Fbcp.15336). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [35349180](https://pubmed.ncbi.nlm.nih.gov/35349180). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [247777754](https://api.semanticscholar.org/CorpusID:247777754).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"25\",\"title\":\"** Tao YX (11 June 2014). [_Pharmacology and Therapeutics of Constitutively Active Receptors_](https://books.google.com/books?id=crNZAwAAQBAJ\u0026pg=PA351). Elsevier Science. pp. 351â€“. [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 978-0-12-417206-7. \\\"ARN-509 is related structurally to enzalutamide with greater in vivo activity in CRPC xenograft models (Clegg et al., 2012).\\\"\",\"description\":\"25. **^** Tao YX (11 June 2014). [_Pharmacology and Therapeutics of Constitutively Active Receptors_](https://books.google.com/books?id=crNZAwAAQBAJ\u0026pg=PA351). Elsevier Science. pp. 351â€“. [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 978-0-12-417206-7. \\\"ARN-509 is related structurally to enzalutamide with greater in vivo activity in CRPC xenograft models (Clegg et al., 2012).\\\"\",\"url\":\"https://books.google.com/books?id=crNZAwAAQBAJ\u0026pg=PA351\",\"favicon\":\"\"},{\"id\":\"26\",\"title\":\"** Joseph JD, Lu N, Qian J, Sensintaffar J, Shao G, Brigham D, et al. (September 2013). [\\\"A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509\\\"](https://doi.org/10.1158%2F2159-8290.CD-13-0226). _Cancer Discovery_. **3** (9): 1020â€“9\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1158/2159-8290.CD-13-0226](https://doi.org/10.1158%2F2159-8290.CD-13-0226). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [23779130](https://pubmed.ncbi.nlm.nih.gov/23779130).\",\"description\":\"26. **^** Joseph JD, Lu N, Qian J, Sensintaffar J, Shao G, Brigham D, et al. (September 2013). [\\\"A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509\\\"](https://doi.org/10.1158%2F2159-8290.CD-13-0226). _Cancer Discovery_. **3** (9): 1020â€“9\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1158/2159-8290.CD-13-0226](https://doi.org/10.1158%2F2159-8290.CD-13-0226). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [23779130](https://pubmed.ncbi.nlm.nih.gov/23779130).\",\"url\":\"https://doi.org/10.1158%2F2159-8290.CD-13-0226\",\"favicon\":\"\"},{\"id\":\"27\",\"title\":\"** Nelson WG, Yegnasubramanian S (September 2013). [\\\"Resistance emerges to second-generation antiandrogens in prostate cancer\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3800038). _Cancer Discovery_. **3** (9): 971â€“4\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1158/2159-8290.CD-13-0405](https://doi.org/10.1158%2F2159-8290.CD-13-0405). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3800038](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3800038). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [24019330](https://pubmed.ncbi.nlm.nih.gov/24019330).\",\"description\":\"27. **^** Nelson WG, Yegnasubramanian S (September 2013). [\\\"Resistance emerges to second-generation antiandrogens in prostate cancer\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3800038). _Cancer Discovery_. **3** (9): 971â€“4\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1158/2159-8290.CD-13-0405](https://doi.org/10.1158%2F2159-8290.CD-13-0405). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3800038](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3800038). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [24019330](https://pubmed.ncbi.nlm.nih.gov/24019330).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3800038\",\"favicon\":\"\"},{\"id\":\"28\",\"title\":\"** Moilanen AM, Riikonen R, Oksala R, Ravanti L, Aho E, Wohlfahrt G, et al. (July 2015). [\\\"Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490394). _Scientific Reports_. **5** 12007\\\\. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[2015NatSR...512007M](https://ui.adsabs.harvard.edu/abs/2015NatSR...512007M). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/srep12007](https://doi.org/10.1038%2Fsrep12007). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [4490394](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490394). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [26137992](https://pubmed.ncbi.nlm.nih.gov/26137992).\",\"description\":\"28. **^** Moilanen AM, Riikonen R, Oksala R, Ravanti L, Aho E, Wohlfahrt G, et al. (July 2015). [\\\"Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490394). _Scientific Reports_. **5** 12007\\\\. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[2015NatSR...512007M](https://ui.adsabs.harvard.edu/abs/2015NatSR...512007M). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/srep12007](https://doi.org/10.1038%2Fsrep12007). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [4490394](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490394). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [26137992](https://pubmed.ncbi.nlm.nih.gov/26137992).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490394\",\"favicon\":\"\"},{\"id\":\"29\",\"title\":\"** Fizazi K, Albiges L, Loriot Y, Massard C (2015). [\\\"ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673554). _Expert Review of Anticancer Therapy_. **15** (9): 1007â€“17\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1586/14737140.2015.1081566](https://doi.org/10.1586%2F14737140.2015.1081566). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [4673554](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673554). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [26313416](https://pubmed.ncbi.nlm.nih.gov/26313416).\",\"description\":\"29. **^** Fizazi K, Albiges L, Loriot Y, Massard C (2015). [\\\"ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673554). _Expert Review of Anticancer Therapy_. **15** (9): 1007â€“17\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1586/14737140.2015.1081566](https://doi.org/10.1586%2F14737140.2015.1081566). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [4673554](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673554). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [26313416](https://pubmed.ncbi.nlm.nih.gov/26313416).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673554\",\"favicon\":\"\"},{\"id\":\"30\",\"title\":\"** Ivachtchenko AV, Mitkin OD, Kudan EV, Rjahovsky AA, Vorobiev AA, Trifelenkov AS, et al. (2014). [\\\"Preclinical Development of ONC1-13B, Novel Antiandrogen for Prostate Cancer Treatment\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3909768). _Journal of Cancer_. **5** (2): 133â€“42\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.7150/jca.7773](https://doi.org/10.7150%2Fjca.7773). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3909768](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3909768). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [24494031](https://pubmed.ncbi.nlm.nih.gov/24494031).\",\"description\":\"30. **^** Ivachtchenko AV, Mitkin OD, Kudan EV, Rjahovsky AA, Vorobiev AA, Trifelenkov AS, et al. (2014). [\\\"Preclinical Development of ONC1-13B, Novel Antiandrogen for Prostate Cancer Treatment\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3909768). _Journal of Cancer_. **5** (2): 133â€“42\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.7150/jca.7773](https://doi.org/10.7150%2Fjca.7773). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3909768](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3909768). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [24494031](https://pubmed.ncbi.nlm.nih.gov/24494031).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3909768\",\"favicon\":\"\"},{\"id\":\"31\",\"title\":\"** [\\\"Reference at www.accessdata.fda.gov\\\"](https://web.archive.org/web/20210827151554/https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203415s011lbl.pdf) (PDF). Archived from [the original](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203415s011lbl.pdf) (PDF) on 27 August 2021. Retrieved 24 February 2018.\",\"description\":\"31. **^** [\\\"Reference at www.accessdata.fda.gov\\\"](https://web.archive.org/web/20210827151554/https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203415s011lbl.pdf) (PDF). Archived from [the original](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203415s011lbl.pdf) (PDF) on 27 August 2021. Retrieved 24 February 2018.\",\"url\":\"https://web.archive.org/web/20210827151554/https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203415s011lbl.pdf\",\"favicon\":\"\"},{\"id\":\"32\",\"title\":\"** Cockshott ID (2004). \\\"Bicalutamide: clinical pharmacokinetics and metabolism\\\". _Clin Pharmacokinet_. **43** (13): 855â€“78\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.2165/00003088-200443130-00003](https://doi.org/10.2165%2F00003088-200443130-00003). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [15509184](https://pubmed.ncbi.nlm.nih.gov/15509184). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [29912565](https://api.semanticscholar.org/CorpusID:29912565).\",\"description\":\"32. **^** Cockshott ID (2004). \\\"Bicalutamide: clinical pharmacokinetics and metabolism\\\". _Clin Pharmacokinet_. **43** (13): 855â€“78\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.2165/00003088-200443130-00003](https://doi.org/10.2165%2F00003088-200443130-00003). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [15509184](https://pubmed.ncbi.nlm.nih.gov/15509184). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [29912565](https://api.semanticscholar.org/CorpusID:29912565).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"33\",\"title\":\"** Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. (2009). [\\\"Development of a second-generation antiandrogen for treatment of advanced prostate cancer\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2981508). _Science_. **324** (5928): 787â€“90\\\\. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[2009Sci...324..787T](https://ui.adsabs.harvard.edu/abs/2009Sci...324..787T). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1126/science.1168175](https://doi.org/10.1126%2Fscience.1168175). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [2981508](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2981508). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [19359544](https://pubmed.ncbi.nlm.nih.gov/19359544).\",\"description\":\"33. **^** Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. (2009). [\\\"Development of a second-generation antiandrogen for treatment of advanced prostate cancer\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2981508). _Science_. **324** (5928): 787â€“90\\\\. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[2009Sci...324..787T](https://ui.adsabs.harvard.edu/abs/2009Sci...324..787T). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1126/science.1168175](https://doi.org/10.1126%2Fscience.1168175). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [2981508](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2981508). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [19359544](https://pubmed.ncbi.nlm.nih.gov/19359544).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2981508\",\"favicon\":\"\"},{\"id\":\"34\",\"title\":\"** Liu B, Su L, Geng J, Liu J, Zhao G (2010). \\\"Developments in nonsteroidal antiandrogens targeting the androgen receptor\\\". _ChemMedChem_. **5** (10): 1651â€“61\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1002/cmdc.201000259](https://doi.org/10.1002%2Fcmdc.201000259). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [20853390](https://pubmed.ncbi.nlm.nih.gov/20853390). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [23228778](https://api.semanticscholar.org/CorpusID:23228778).\",\"description\":\"34. **^** Liu B, Su L, Geng J, Liu J, Zhao G (2010). \\\"Developments in nonsteroidal antiandrogens targeting the androgen receptor\\\". _ChemMedChem_. **5** (10): 1651â€“61\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1002/cmdc.201000259](https://doi.org/10.1002%2Fcmdc.201000259). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [20853390](https://pubmed.ncbi.nlm.nih.gov/20853390). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [23228778](https://api.semanticscholar.org/CorpusID:23228778).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"35\",\"title\":\"_**a**_ _**b**_ [\\\"Apalutamide - Janssen Research and Development\\\"](http://adisinsight.springer.com/drugs/800032695). _AdisInsight_. Springer Nature Switzerland AG. [Archived](https://web.archive.org/web/20190103110524/https://adisinsight.springer.com/drugs/800032695) from the original on 3 January 2019. Retrieved 6 September 2015.\",\"description\":\"35. ^ _**a**_ _**b**_ [\\\"Apalutamide - Janssen Research and Development\\\"](http://adisinsight.springer.com/drugs/800032695). _AdisInsight_. Springer Nature Switzerland AG. [Archived](https://web.archive.org/web/20190103110524/https://adisinsight.springer.com/drugs/800032695) from the original on 3 January 2019. Retrieved 6 September 2015.\",\"url\":\"http://adisinsight.springer.com/drugs/800032695\",\"favicon\":\"\"},{\"id\":\"36\",\"title\":\"** [US 20100190991](https://patents.google.com/patent/US20100190991A1), Ouerfelli O, Dilhas A, Yang G, Zhao H, \\\"Synthesis of thiohydantoins\\\", issued 11 June 2013, assigned to Sloan Kettering Institute for Cancer Research.  [Archived](https://web.archive.org/web/20211105010300/https://patents.google.com/patent/US20100190991A1) 5 November 2021 at the [Wayback Machine](Wayback_Machine \\\"Wayback Machine\\\")\",\"description\":\"36. **^** [US 20100190991](https://patents.google.com/patent/US20100190991A1), Ouerfelli O, Dilhas A, Yang G, Zhao H, \\\"Synthesis of thiohydantoins\\\", issued 11 June 2013, assigned to Sloan Kettering Institute for Cancer Research.  [Archived](https://web.archive.org/web/20211105010300/https://patents.google.com/patent/US20100190991A1) 5 November 2021 at the [Wayback Machine](Wayback_Machine \\\"Wayback Machine\\\")\",\"url\":\"https://patents.google.com/patent/US20100190991A1\",\"favicon\":\"\"},{\"id\":\"37\",\"title\":\"** Rathkopf DE, Morris MJ, Fox JJ, Danila DC, Slovin SF, Hager JH, et al. (October 2013). [\\\"Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782148). _Journal of Clinical Oncology_. **31** (28): 3525â€“3530\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1200/JCO.2013.50.1684](https://doi.org/10.1200%2FJCO.2013.50.1684). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3782148](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782148). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [24002508](https://pubmed.ncbi.nlm.nih.gov/24002508).\",\"description\":\"37. **^** Rathkopf DE, Morris MJ, Fox JJ, Danila DC, Slovin SF, Hager JH, et al. (October 2013). [\\\"Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782148). _Journal of Clinical Oncology_. **31** (28): 3525â€“3530\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1200/JCO.2013.50.1684](https://doi.org/10.1200%2FJCO.2013.50.1684). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3782148](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782148). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [24002508](https://pubmed.ncbi.nlm.nih.gov/24002508).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782148\",\"favicon\":\"\"},{\"id\":\"38\",\"title\":\"** Smith MR, Liu G, Shreeve SM, Matheny S, Sosa A, Kheoh TS, et al. _A randomized double-blind, comparative study of ARN-509 plus androgen deprivation therapy (ADT) versus ADT alone in nonmetastatic castration-resistant prostate cancer (M0-CRPC): The SPARTAN trial_. 2014 ASCO Annual Meeting. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1200/jco.2014.32.15_suppl.tps5100](https://doi.org/10.1200%2Fjco.2014.32.15_suppl.tps5100).\",\"description\":\"38. **^** Smith MR, Liu G, Shreeve SM, Matheny S, Sosa A, Kheoh TS, et al. _A randomized double-blind, comparative study of ARN-509 plus androgen deprivation therapy (ADT) versus ADT alone in nonmetastatic castration-resistant prostate cancer (M0-CRPC): The SPARTAN trial_. 2014 ASCO Annual Meeting. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1200/jco.2014.32.15_suppl.tps5100](https://doi.org/10.1200%2Fjco.2014.32.15_suppl.tps5100).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"39\",\"title\":\"** Bossi A, Dearnaley D, McKenzie M, Baskin-Bey E, Tyler R, Tombal B, et al. (2016). [\\\"ATLAS: A phase 3 trial evaluating the efficacy of apalutamide (ARN-509) in patients with high-risk localized or locally advanced prostate cancer receiving primary radiation therapy\\\"](https://doi.org/10.1093%2Fannonc%2Fmdw372.52). _Annals of Oncology_. **27** (suppl_6): vi263. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1093/annonc/mdw372.52](https://doi.org/10.1093%2Fannonc%2Fmdw372.52). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0923-7534](https://search.worldcat.org/issn/0923-7534).\",\"description\":\"39. **^** Bossi A, Dearnaley D, McKenzie M, Baskin-Bey E, Tyler R, Tombal B, et al. (2016). [\\\"ATLAS: A phase 3 trial evaluating the efficacy of apalutamide (ARN-509) in patients with high-risk localized or locally advanced prostate cancer receiving primary radiation therapy\\\"](https://doi.org/10.1093%2Fannonc%2Fmdw372.52). _Annals of Oncology_. **27** (suppl_6): vi263. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1093/annonc/mdw372.52](https://doi.org/10.1093%2Fannonc%2Fmdw372.52). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0923-7534](https://search.worldcat.org/issn/0923-7534).\",\"url\":\"https://doi.org/10.1093%2Fannonc%2Fmdw372.52\",\"favicon\":\"\"},{\"id\":\"40\",\"title\":\"** Chi K, Chowdhury S, Radziszewski P, Lebret T, Ozguroglu M, Sternberg C, et al. (2016). [\\\"TITAN: A randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC)\\\"](https://doi.org/10.1093%2Fannonc%2Fmdw372.54). _Annals of Oncology_. **27** (suppl_6): vi265. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1093/annonc/mdw372.54](https://doi.org/10.1093%2Fannonc%2Fmdw372.54). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0923-7534](https://search.worldcat.org/issn/0923-7534).`{{cite journal}}`: CS1 maint: overridden setting (link)\",\"description\":\"40. **^** Chi K, Chowdhury S, Radziszewski P, Lebret T, Ozguroglu M, Sternberg C, et al. (2016). [\\\"TITAN: A randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC)\\\"](https://doi.org/10.1093%2Fannonc%2Fmdw372.54). _Annals of Oncology_. **27** (suppl_6): vi265. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1093/annonc/mdw372.54](https://doi.org/10.1093%2Fannonc%2Fmdw372.54). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0923-7534](https://search.worldcat.org/issn/0923-7534).`{{cite journal}}`: CS1 maint: overridden setting (link)\",\"url\":\"https://doi.org/10.1093%2Fannonc%2Fmdw372.54\",\"favicon\":\"\"},{\"id\":\"41\",\"title\":\"** [\\\"Janssen Submits New Drug Application to U.S. FDA for Apalutamide (ARN-509) to Treat Men with Non-Metastatic Castration-Resistant Prostate Cancer\\\"](https://www.prnewswire.com/news-releases/janssen-submits-new-drug-application-to-us-fda-for-apalutamide-arn-509-to-treat-men-with-non-metastatic-castration-resistant-prostate-cancer-300534704.html) (Press release). Janssen. [Archived](https://web.archive.org/web/20180215084131/https://www.prnewswire.com/news-releases/janssen-submits-new-drug-application-to-us-fda-for-apalutamide-arn-509-to-treat-men-with-non-metastatic-castration-resistant-prostate-cancer-300534704.html) from the original on 15 February 2018. Retrieved 15 February 2018 â€“ via PR Newswire.\",\"description\":\"41. **^** [\\\"Janssen Submits New Drug Application to U.S. FDA for Apalutamide (ARN-509) to Treat Men with Non-Metastatic Castration-Resistant Prostate Cancer\\\"](https://www.prnewswire.com/news-releases/janssen-submits-new-drug-application-to-us-fda-for-apalutamide-arn-509-to-treat-men-with-non-metastatic-castration-resistant-prostate-cancer-300534704.html) (Press release). Janssen. [Archived](https://web.archive.org/web/20180215084131/https://www.prnewswire.com/news-releases/janssen-submits-new-drug-application-to-us-fda-for-apalutamide-arn-509-to-treat-men-with-non-metastatic-castration-resistant-prostate-cancer-300534704.html) from the original on 15 February 2018. Retrieved 15 February 2018 â€“ via PR Newswire.\",\"url\":\"https://www.prnewswire.com/news-releases/janssen-submits-new-drug-application-to-us-fda-for-apalutamide-arn-509-to-treat-men-with-non-metastatic-castration-resistant-prostate-cancer-300534704.html\",\"favicon\":\"\"},{\"id\":\"42\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ [\\\"Apalutamide Monograph for Professionals\\\"](https://www.drugs.com/monograph/apalutamide.html). _Drugs.com_. 10 April 2024. [Archived](https://web.archive.org/web/20221210045939/https://www.drugs.com/monograph/apalutamide.html) from the original on 10 December 2022. Retrieved 16 August 2024.\",\"description\":\"42. ^ _**a**_ _**b**_ _**c**_ _**d**_ [\\\"Apalutamide Monograph for Professionals\\\"](https://www.drugs.com/monograph/apalutamide.html). _Drugs.com_. 10 April 2024. [Archived](https://web.archive.org/web/20221210045939/https://www.drugs.com/monograph/apalutamide.html) from the original on 10 December 2022. Retrieved 16 August 2024.\",\"url\":\"https://www.drugs.com/monograph/apalutamide.html\",\"favicon\":\"\"},{\"id\":\"43\",\"title\":\"** [World Health Organization](World_Health_Organization \\\"World Health Organization\\\") (2016). \\\"International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 75\\\". _WHO Drug Information_. **30** (1). [hdl](Hdl_\\\\(identifier\\\\) \\\"Hdl \\\\(identifier\\\\)\\\"):[10665/331046](https://hdl.handle.net/10665%2F331046).\",\"description\":\"43. **^** [World Health Organization](World_Health_Organization \\\"World Health Organization\\\") (2016). \\\"International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 75\\\". _WHO Drug Information_. **30** (1). [hdl](Hdl_\\\\(identifier\\\\) \\\"Hdl \\\\(identifier\\\\)\\\"):[10665/331046](https://hdl.handle.net/10665%2F331046).\",\"url\":\"World_Health_Organization \\\"World Health Organization\\\"\",\"favicon\":\"\"}],\"images\":[],\"fixedIssues\":[{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"approved for the treatment of prostate cancer in February 2018.[8][9][10][15]\",\"explanation\":\"Reference [15] is a 2007 patent (WO 2007126765) that describes the compound but does not support the claim of FDA approval in 2018.\",\"fixedText\":\"Remove [15] from the citations for the approval claim; retain it only for the \\\"first described in 2007\\\" if applicable, or adjust sentence structure to separate claims.\",\"evidenceSource\":\"[15]\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"No specific mention of expanded indications.\",\"explanation\":\"The introduction omits the 2019 FDA expansion to metastatic castration-sensitive prostate cancer (mCSPC), limiting the scope of current medical uses as of 2025. This is a knowledge gap in recent updates affecting applicability.\",\"fixedText\":\"Add to the first paragraph: specify uses as \\\"non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC)\\\" with citation to updated FDA label or approval.\",\"evidenceSource\":\"FDA approval announcement, September 17, 2019: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-apalutamide-metastatic-castration-sensitive-prostate-cancer\"},{\"criticality\":\"Critical\",\"issueType\":\"Scope/Applicability Misstatement\",\"problematicText\":\"It is also a promising potential treatment for metastatic castration-resistant prostate cancer (mCRPC), which the NSAA enzalutamide and the androgen synthesis inhibitor abiraterone acetate are used to treat.[13]\",\"explanation\":\"Apalutamide is not approved or established as a treatment for mCRPC; its indications are limited to nmCRPC and mCSPC. The claim misstates the scope of its medical uses by including an unapproved, speculative application, potentially misleading readers on treatment options.\",\"fixedText\":\"Remove the sentence entirely to align with approved indications.\",\"evidenceSource\":\"Ref 2 (DailyMed label); [](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d1cda4f7-cb33-46ea-b9ac-431f6452b1a5)\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"\",\"explanation\":\"The section details the use of apalutamide with androgen deprivation therapy specifically for nmCRPC but omits the equivalent combination requirement for mCSPC, creating an incomplete and unbalanced description of its medical applications.\",\"fixedText\":\"Add a sentence or integrate details specifying that apalutamide is used with androgen deprivation therapy for mCSPC as well.\",\"evidenceSource\":\"Ref 2 (DailyMed label); [](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d1cda4f7-cb33-46ea-b9ac-431f6452b1a5)\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"Contraindications of apalutamide include pregnancy and a history of or susceptibility to seizures.[2]\",\"explanation\":\"The FDA label (ref [2]) lists no general contraindications in section 4, but specifies in section 8.1 that apalutamide is contraindicated in females who are or may become pregnant. However, a history of or susceptibility to seizures is not listed as a contraindication; it is addressed under warnings and precautions (section 5.2), where patients with such history were excluded from trials, and seizures require discontinuation, but it is not contraindicated.\",\"fixedText\":\"Correct to state that apalutamide is contraindicated in pregnant women (or females who may become pregnant). Remove or rephrase the seizures claim to note it as a precaution rather than contraindication, or move to side effects/warnings section if appropriate. Since this is contraindications section, only include actual contraindications.\",\"evidenceSource\":\"[2] and FDA label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210951s016lbl.pdf\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"\",\"explanation\":\"The section does not mention that the drug is primarily for males with prostate cancer, making the pregnancy contraindication contextually important. Also, no mention of hypersensitivity as a potential contraindication in international contexts (e.g., EMA), though US label does not list it explicitly under contraindications.\",\"fixedText\":\"Add clarification that pregnancy contraindication applies to females, and note regional differences if relevant, but keep focused on US/FDA since primary ref.\",\"evidenceSource\":\"EMA product information: https://www.ema.europa.eu/en/documents/product-information/erleada-epar-product-information_en.pdf\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"with the most common [side effects](Side_effect \\\"Side effect\\\") reported when added to [surgical](Surgical_castration \\\"Surgical castration\\\") or [medical castration](Medical_castration \\\"Medical castration\\\") including [fatigue](Fatigue_\\\\(medical\\\\) \\\"Fatigue \\\\(medical\\\\)\\\"), [nausea](Nausea \\\"Nausea\\\"), [abdominal pain](Abdominal_pain \\\"Abdominal pain\\\"), and [diarrhea](Diarrhea \\\"Diarrhea\\\").[11][12][20]\",\"explanation\":\"Citations [11], [12], and [20] primarily discuss side effects of other antiandrogens like abiraterone or general AR antagonists, without specifically listing these as the most common for apalutamide from clinical trials.\",\"fixedText\":\"Replace citations [11][12][20] with [2] and [10], as they provide specific data on apalutamide adverse reactions from the prescribing information and review.\",\"evidenceSource\":\"[2]\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"No specific text; refers to the incomplete list of most common side effects.\",\"explanation\":\"The section omits hypertension and rash, which are among the most common adverse reactions (incidence â‰¥20% in SPARTAN and TITAN trials), potentially understating cardiovascular and dermatologic risks important for patient safety and monitoring.\",\"fixedText\":\"Add hypertension and rash to the list of most common side effects, citing [2].\",\"evidenceSource\":\"[2]\"},{\"criticality\":\"Critical\",\"issueType\":\"Quantitative/Units Error\",\"problematicText\":\"Peak concentrations for 160 mg/day apalutamide at steady-state are 6.0 Î¼g/mL (12.5 Î¼mol/L)\",\"explanation\":\"The standard and approved dose of apalutamide is 240 mg/day. The reported Cmax of 6.0 Î¼g/mL corresponds to steady-state levels at 240 mg/day, not 160 mg/day (which is the dose for enzalutamide). This error misstates the dose-exposure relationship, potentially misleading on pharmacokinetics and comparisons.\",\"fixedText\":\"Replace \\\"160 mg/day\\\" with \\\"240 mg/day\\\" in the sentence.\",\"evidenceSource\":\"[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210951s017lbl.pdf)\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"\\\"It was first described in the literature in a United States patent application that was published in November 2007 and in another that was submitted in July 2010.[15][36]\\\"\",\"explanation\":\"Reference [15] is a PCT/WO international patent application (WO 2007126765A2, filed May 4, 2007, published Nov 8, 2007), not a United States patent application. Reference [36] is US application 12/397,308 (US 20100190991A1), filed March 3, 2009, and published July 29, 2010â€”not submitted in July 2010. This misrepresents the patent history, potentially misleading on the timeline of development.\",\"fixedText\":\"Revise to: \\\"first described in a 2007 patent application published in November 2007 [15] and its synthesis in a US patent application filed in March 2009 and published in July 2010 [36].\\\"\",\"evidenceSource\":\"WO 2007126765: https://worldwide.espacenet.com/patent/search/family/037340259/publication/WO2007126765A2?q=WO2007126765 ; US 20100190991A1: https://patents.google.com/patent/US20100190991A1/en\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"No specific text; overall section lacks detail on intermediate developer.\",\"explanation\":\"The section omits that apalutamide (ARN-509) was licensed from the University of California to Aragon Pharmaceuticals, which advanced it through preclinical and early clinical stages (phase I/II trials), before Aragon's acquisition by Johnson \u0026 Johnson in 2013, after which Janssen continued development. This gap leaves an incomplete development history, as early trials (e.g., refs [14], [37]) were conducted by Aragon.\",\"fixedText\":\"Add: \\\"It was licensed to Aragon Pharmaceuticals, which conducted preclinical development and early clinical trials. In August 2013, Johnson \u0026 Johnson acquired Aragon, and Janssen Research \u0026 Development continued development.[new ref]\\\"\",\"evidenceSource\":\"[14]; [37]; Acquisition: https://www.jnj.com/media-center/press-releases/johnson-johnson-completes-acquisition-of-aragon-pharmaceuticals-inc\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency | Missing Information\",\"problematicText\":\"Apalutamide is available in the United States, Canada, the European Union, and Australia.[2][8][9][42][6]\",\"explanation\":\"The subsection on availability does not mention the recent approval of the first generic version of apalutamide in the United States in March 2025, which impacts access, cost, and market dynamics as of October 2025. This omission affects the currency of information on the drug's societal availability.\",\"fixedText\":\"Add the following sentence to the availability subsection: As of March 2025, a generic version of apalutamide is available in the United States.[](https://www.drugs.com/availability/generic-erleada.html)\",\"evidenceSource\":\"[](https://www.drugs.com/availability/generic-erleada.html)\"}],\"slug\":\"Apalutamide\",\"title\":\"Apalutamide\",\"content\":\"$1f\",\"description\":\"Apalutamide\\n\\nApalutamide , sold under the brand name Erleada among others, is a nonsteroidal antiandrogen (NSAA) medication used for the treatment of prostate cancer, including non-metastatic...\",\"metadata\":{\"categories\":[\"Erleada\",\"ARN-509\"],\"lastModified\":\"1761553636\",\"contentLength\":\"19315\",\"version\":\"1.0\",\"lastEditor\":\"system\",\"language\":\"en\",\"isRedirect\":false,\"redirectTarget\":\"\",\"isWithheld\":false},\"stats\":{\"totalViews\":\"25006\",\"recentViews\":\"25006\",\"dailyAvgViews\":833.5333251953125,\"qualityScore\":1,\"lastViewed\":\"1761883423\"},\"linkedPages\":null},\"found\":true},\"dataUpdateCount\":1,\"dataUpdatedAt\":1761883424116,\"error\":null,\"errorUpdateCount\":0,\"errorUpdatedAt\":0,\"fetchFailureCount\":0,\"fetchFailureReason\":null,\"fetchMeta\":null,\"isInvalidated\":false,\"status\":\"success\",\"fetchStatus\":\"idle\"},\"queryKey\":[\"page\",\"Apalutamide\"],\"queryHash\":\"[\\\"page\\\",\\\"Apalutamide\\\"]\"}]},\"children\":\"$L20\"}]\n"])</script><script nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy">self.__next_f.push([1,"c:{\"metadata\":[[\"$\",\"title\",\"0\",{\"children\":\"Apalutamide\"}],[\"$\",\"meta\",\"1\",{\"name\":\"description\",\"content\":\"Apalutamide , sold under the brand name Erleada among others, is a nonsteroidal antiandrogen (NSAA) medication used for the treatment of prostate cancer, including non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC).[2][8][9][8] It is an androgen receptor inhibitor.[2] It is taken by mouth.[2][10] Side effects of apalutamide when added to castration include fatigue, nausea, abdominal pain, diarrhea, high blood pressure, rash,...\"}],[\"$\",\"meta\",\"2\",{\"name\":\"author\",\"content\":\"system\"}],[\"$\",\"link\",\"3\",{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\",\"crossOrigin\":\"$undefined\"}],[\"$\",\"meta\",\"4\",{\"name\":\"keywords\",\"content\":\"Erleada, ARN-509\"}],[\"$\",\"meta\",\"5\",{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",\"6\",{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"link\",\"7\",{\"rel\":\"canonical\",\"href\":\"https://grokipedia.com/page/Apalutamide\"}],[\"$\",\"meta\",\"8\",{\"property\":\"og:title\",\"content\":\"Apalutamide\"}],[\"$\",\"meta\",\"9\",{\"property\":\"og:description\",\"content\":\"Apalutamide , sold under the brand name Erleada among others, is a nonsteroidal antiandrogen (NSAA) medication used for the treatment of prostate cancer, including non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC).[2][8][9][8] It is an androgen receptor inhibitor.[2] It is taken by mouth.[2][10] Side effects of apalutamide when added to castration include fatigue, nausea, abdominal pain, diarrhea, high blood pressure, rash,...\"}],[\"$\",\"meta\",\"10\",{\"property\":\"og:url\",\"content\":\"https://grokipedia.com/page/Apalutamide\"}],[\"$\",\"meta\",\"11\",{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",\"12\",{\"property\":\"og:locale\",\"content\":\"en\"}],[\"$\",\"meta\",\"13\",{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",\"14\",{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",\"15\",{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",\"16\",{\"property\":\"og:image:alt\",\"content\":\"Apalutamide\"}],[\"$\",\"meta\",\"17\",{\"property\":\"og:type\",\"content\":\"article\"}],[\"$\",\"meta\",\"18\",{\"property\":\"article:modified_time\",\"content\":\"1970-01-21T09:19:13.636Z\"}],[\"$\",\"meta\",\"19\",{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",\"20\",{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",\"21\",{\"name\":\"twitter:title\",\"content\":\"Apalutamide\"}],[\"$\",\"meta\",\"22\",{\"name\":\"twitter:description\",\"content\":\"Apalutamide , sold under the brand name Erleada among others, is a nonsteroidal antiandrogen (NSAA) medication used for the treatment of prostate cancer, including non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC).[2][8][9][8] It is an androgen receptor inhibitor.[2] It is taken by mouth.[2][10] Side effects of apalutamide when added to castration include fatigue, nausea, abdominal pain, diarrhea, high blood pressure, rash,...\"}],[\"$\",\"meta\",\"23\",{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"link\",\"24\",{\"rel\":\"icon\",\"href\":\"/favicon.ico\",\"type\":\"image/x-icon\",\"sizes\":\"16x16\"}],[\"$\",\"$L21\",\"25\",{}]],\"error\":null,\"digest\":\"$undefined\"}\n"])</script><script nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy">self.__next_f.push([1,"11:\"$c:metadata\"\n"])</script><script nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy">self.__next_f.push([1,"22:I[61172,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"PageEditorProvider\"]\n"])</script><script nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy">self.__next_f.push([1,"23:I[63493,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="MDlmYWVkYmYtODBiMS00YjZiLWEyODEtODI5NTgzZGZlYTEy">self.__next_f.push([1,"20:[\"$\",\"$L22\",null,{\"children\":[\"$\",\"$L23\",null,{\"slug\":\"Apalutamide\"}]}]\n"])</script></body></html>